Document:

Document

EMPLOYMENT AGREEMENT
This Employment Agreement (“Agreement”) is made as of the 18th of June, 2020 between Axcella Health Inc., a Delaware corporation (the “Company”), and Andrew Suchoff (the “Executive”).  
WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein commencing on June 29, 2020, unless another date is agreed to by the parties.  The Executive’s first day of employment shall be the “Effective Date” of this Agreement; and
WHEREAS, the Company provided the Executive with this Agreement, which is its formal offer of employment to the Executive, at least ten (10) business days before the Effective Date.  The Executive has the right to consult with counsel prior to signing this Agreement.  
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
1.Employment.
(a)Term.  The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”).  The Executive’s employment with the Company shall be “at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.
(b)Position and Duties.  During the Term, the Executive shall serve as the Senior Vice President, Chief People Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the “CEO”).  The Executive shall devote their full working time and efforts to the business and affairs of the Company.  Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive’s performance of their duties to the Company. Executive may continue serving on the board of directors for Home for Little Wanderers and Seeding Labs during the Term so long as such services do not interfere with the Executive’s performance of his duties and obligations to the Company hereunder.
2.Compensation and Related Matters.
(a)Base Salary.  During the Term, the Executive’s initial annual base salary shall be paid at the rate of $340,000 per year.  The Executive’s base salary shall be reviewed annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”).  The base salary in effect at any given time is referred to herein as “Base Salary.”  

The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.
(b)Incentive Compensation.  During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time.  The Executive’s target annual incentive compensation shall be 40% percent of the Base Salary (the “Target Bonus”).  Except as otherwise provided herein, to earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.
(c)Expenses.  The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by them during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executives.
(d)Other Benefits.  During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s policies and employee benefit plans in effect from time to time, subject to the terms of such policies and plans and to the Company’s ability to amend, modify, replace or terminate such policies and plans, including with respect to paid time off.
(e)Equity.  Subject to final approval by the Board promptly on or after the Effective Date, the Company shall grant Executive Option Award: an option to purchase 84,200 shares of the Company’s Common Stock, par value $0.001 per share (“Shares”) with an exercise price per Share equal to the closing trading price per share of the Company’s common stock on the Nasdaq Global Market (“FMV”) on the date the grant is approved by the Board ("Grant Date”), subject to the terms of and contingent upon Executive’s execution of a stock option award agreement issued pursuant to and under the terms of the Axcella Health Inc. 2019 Stock Option and Incentive Plan, as amended from time to time (the “Stock Plan”). To the extent permitted by law and subject to Board approval, this Option Award shall be granted in the form of an incentive stock option meeting the requirements of Section 422 of the Code except to the extent that Executive directs that the Option Award be granted in whole or in part in the form of a non-qualified stock option. Subject to final approval by the Board, the Option Award shall vest 25% on the first anniversary of the Effective Date, respectively, thereafter the remaining 75% of the Option Award shall vest in equal installments on a quarterly basis on the last day of each complete quarter over a period of three years following such first anniversary, provided that Executive remains employed by the Company on each vesting day.
(f)The Option Award set forth above  shall be subject to the specific terms and conditions of the Stock Plan and stock option award agreements , in the case of inconsistency between this Agreement, and the Stock Plan, the provision in the Stock Plan shall govern; in the case of inconsistency between this Agreement and any stock option award agreement , the provision in stock option agreement shall govern.  
(g)Remote Working; Lodging.  Executive will be required to work at Axcella’s offices and may work remotely at times with the approval of the Chief Executive 
        2

Officer (“CEO”), which approval shall be at the CEO’s sole discretion subject to any applicable laws and regulations. Executive may stay overnight in lodging near Axcella’s offices to enable him to perform his work obligations, as agreed with the CEO, and the Company will reimburse Executive for overnight lodging up to $600 per week.
(h)Withholding; Tax Effect.  All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.
3.Termination.  During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:
(a)Death.  The Executive’s employment hereunder shall terminate upon    their death.
(b)Disability.  The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.  If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.  The Executive shall cooperate with any reasonable request of the physician in connection with such certification.  If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive.  Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.  
(c)Termination by Company for Cause.  The Company may terminate the Executive’s employment hereunder for Cause.  For purposes of this Agreement, “Cause” shall mean:  (i) conduct by the Executive constituting a material act of misconduct in connection with the performance of their duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any conduct by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates if they were retained in their position; (iii) unsatisfactory performance by the Executive of a material 
        3

responsibility (other than by reason of the Executive’s physical or mental illness, incapacity or disability) as reasonably determined by the CEO, which has continued for not less than 30 days following written notice from the CEO that identifies the unsatisfactory performance; (iv) a breach by the Executive of any of the provisions contained in Section 8 of this Agreement; (v) a material violation by the Executive of the Company’s written employment policies; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.
(d)Termination without Cause.  The Company may terminate the Executive’s employment hereunder at any time without Cause.  Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.
(e)Termination by the Executive.  The Executive may terminate their employment hereunder at any time for any reason, including but not limited to Good Reason.  For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events:  (i) a material diminution in the Executive’s responsibilities, authority or duties; (ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company; or (iv) the material breach of this Agreement by the Company.  “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period.  If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.
(f)Notice of Termination.  Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.
(g)Date of Termination.  “Date of Termination” shall mean:  (i) if the Executive’s employment is terminated by their death, the date of their death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the 
        4

Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.  Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.
4.Termination Generally.  If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to their authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).
5.Termination by the Company without Cause or by the Executive for Good Reason.  During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates their employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive their Accrued Benefit.  In addition, subject to the Executive (i) signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims in favor of the Company and related persons and entities, a reaffirmation of the Executive’s post-employment obligations, and in the Company’s sole discretion, a one year noncompetition agreement, and shall provide that, if the Executive breaches any of the post-employment obligations, all payment of the Severance Amount shall immediately cease (the “Separation Agreement and Release”), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such period as set forth in the Separation Agreement and Release):
(i)the Company shall pay the Executive an amount equal to nine (9) months of the Executive’s Base Salary (the “Severance Amount”), provided in the event the Executive is entitled to any payments pursuant to Section 8(h)(iii) below, the Severance Amount received in any calendar year will be reduced by the amount the Executive is paid in the same such calendar year pursuant to the Section 8(h)(iii) below, (the “Restrictive Covenants Agreement Setoff”);  and
(ii)subject to the Executive’s copayment of premium amounts at the active employees’ rate and the Executive’s proper election to receive benefits under the 
        5

Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the nine (9) month anniversary of the Date of Termination; (B) the Executive’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company will convert such payments to payroll payments directly to the Executive for the time period specified above.  Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.  For the avoidance of doubt, the taxable payments described above may be used for any purpose, including, but not limited to, continuation coverage under COBRA.
The amounts payable under this Section 5(i) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).
6.Change in Control Payment.  The provisions of this Section 6 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company.  These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to their assigned duties and their objectivity during the pendency and after the occurrence of any such event.  These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 5 regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control (the “Change in Control Period”).  These provisions shall terminate and be of no further force or effect beginning after the Change in Control Period has ended.
(a)Change in Control.  During the Term, if during the Change in Control Period, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates their employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination: 
        6

(i)the Company shall pay the Executive a lump sum in cash in an amount equal to one (1) times the sum of (A) the Executive’s then current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s Target Bonus for the then-current year (the “Change in Control Payment”), provided the Change in Control Payment shall be reduced by the amount of the Restrictive Covenants Agreement Setoff, if applicable, paid or to be paid in the same calendar year; and 
(ii)notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all time-based stock options and other stock-based awards subject to time-based vesting held by the Executive (the “Time-Based Equity Awards”) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the Effective Date of the Separation Agreement and Release (the “Accelerated Vesting Date”); provided that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the Effective Date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein.  Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Executive’s Date of Termination and the Accelerated Vesting Date; and
(iii)subject to the Executive’s copayment of premium amounts at the active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the Executive’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company will convert such payments to payroll payments directly to the Executive for the time period specified above.  Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.  For the avoidance of doubt, the taxable payments described above may be used for any purpose, including, but not limited to, continuation coverage under COBRA.
The amounts payable under this Section 6(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.
(b)Additional Limitation.
        7

a.Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:  (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).
b.For purposes of this Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. 
c.The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.  Any determination by the Accounting Firm shall be binding upon the Company and the Executive.
i.Definitions.  For purposes of this Section 6, the following terms shall have the following meanings:
“Change in Control” shall have the meaning of “Sale Event” as defined in the Stock Plan or any successor plan.  
        8

7.Section 409A.
ii.Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.  
iii.All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided, or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
iv.To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.”  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A1(h).
v.The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A2(b)(2).  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
vi.The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to 
        9

constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
8.Confidential Information, Assignment, Nonsolicitation and Noncompetition.
vii.Proprietary Information.  Executive agrees that all information, whether or not in writing, concerning the Company’s business, technology, business relationships or financial affairs that the Company has not released to the general public (collectively, “Proprietary Information”) and all tangible embodiments thereof are and will be the exclusive property of the Company.  By way of illustration, Proprietary Information may include information or material that has not been made generally available to the public, such as:  (a) corporate information, including plans, strategies, methods, policies, resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, client or business partner identities or other information about customers or clients, business partners, prospect identities or other information about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists;  (d) operational and scientific information, including plans, specifications, manuals, forms, templates, software, pre-clinical and clinical testing data and strategies, research and development strategies, designs, methods, procedures, formulae, data, reports, discoveries, inventions, improvements, concepts, ideas, and other Developments (as defined below), know-how and trade secrets; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, performance evaluations and termination arrangements or documents.  Proprietary Information also includes information received in confidence by the Company from its customers, suppliers, business partners or other third parties.
viii.Recognition of Company’s Rights.  Executive will not, at any time, without the Company’s prior written permission, either during or after their employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of Executive’s duties as an employee of the Company.  Executive will cooperate with the Company and use their best efforts to prevent the unauthorized disclosure of all Proprietary Information. Executive will deliver to the Company all copies and other tangible embodiments of Proprietary Information in their possession or control upon the earlier of a request by the Company or termination of Executive’s employment.
ix.Rights of Others.  Executive understands that the Company is now and may hereafter be subject to nondisclosure or confidentiality agreements with third persons that require the Company to protect or refrain from use or disclosure of proprietary information.  Executive agrees to be bound by the terms of such agreements in the event Executive has access to such proprietary information. Executive understands that the Company strictly prohibits Executive from using or disclosing confidential or proprietary information belonging to any other person or entity (including any employer or former employer), in connection with Executive’s employment. In addition, Executive agrees not to bring any confidential information belonging to any other person or entity onto Company premises or into Company workspaces.  
        10

x.Commitment to Company; Avoidance of Conflict of Interest.  While an employee of the Company, Executive will devote their full-time efforts to the Company’s business and Executive will not, directly or indirectly, engage in any other business activity, except as expressly authorized in writing and in advance by a duly authorized representative of the Company.  Executive will advise an authorized officer of the Company or their designee at such time as any activity of either the Company or another business presents Executive with a conflict of interest or the appearance of a conflict of interest as an employee of the Company.  Executive will take whatever action is requested of them by the Company to resolve any conflict or appearance of conflict which it finds to exist. 
xi.Developments. Executive will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, data, databases, computer programs, research, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship, and other intellectual property, including works-in-process (collectively “Developments”) whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by Executive  (alone or jointly with others) or under my direction during the period of their employment. Executive acknowledges that all work performed by them is on a “work for hire” basis, and Executive hereby does assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns all their right, title and interest in and to all Developments that (a) relate to the business of the Company or any customer of, supplier to or business partner of the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such products or services; or (b) result from tasks assigned to them by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (“Company-Related Developments”), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, sui generis database rights and other intellectual property rights in all countries and territories worldwide and under any international conventions (“Intellectual Property Rights”).  
To preclude any possible uncertainty, if there are any Developments that Executive has, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of their employment with the Company that Executive considers to be their property or the property of third parties and that Executive wishes to have excluded from the scope of this Agreement (“Prior Inventions”), Executive has set forth on Exhibit A attached hereto a complete list of those Prior Inventions.  If disclosure of any such Prior Invention would cause them to violate any prior confidentiality agreement, Executive understands that Executive is not to list such Prior Inventions in Exhibit A but is only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason.  If there are any patents or patent applications in which Executive is named as an inventor, other than those that have been assigned to the Company (“Other Patent Rights”), Executive has also listed those Other Patent Rights on Exhibit A.  If no such disclosure is attached, Executive represents that there are no Prior Inventions or Other Patent Rights.  If, in the course of their employment with the Company, Executive incorporates a Prior Invention into 
        11

a Company product, process or machine, research or development program, or other work done for the Company, Executive hereby grants to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, worldwide license (with the full right to sublicense through multiple tiers) to make, have made, modify, use, sell, offer for sale and import such Prior Invention.  Notwithstanding the foregoing, Executive will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company’s prior written consent.
This Agreement does not obligate Executive to assign to the Company any Development that, in the sole judgment of the Company, reasonably exercised, is developed entirely on Executive’s own time and does not relate to the business efforts or research and development efforts in which, during the period of their employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company.  However, Executive will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion. Executive understands that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section 8(e) will be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes. Executive also hereby waives all claims to any moral rights or other special rights that Executive may have or accrue in any Company-Related Developments.
xii.Documents and Other Materials. Executive will keep and maintain adequate and current records of all Proprietary Information and Company-Related Developments developed by them during their employment, which records will be available to and remain the sole property of the Company at all times. 
All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, blueprints, models, prototypes, or other written, photographic or other tangible material containing Proprietary Information, whether created by  them or others, which come into their custody or possession, are the exclusive property of the Company to be used by them only in the performance of their  duties for the Company.  Any property situated on the Company’s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.  In the event of the termination of their employment for any reason, Executive will deliver to the Company all Company property and equipment in their possession, custody or control, including all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, blueprints, models, prototypes, or other written, photographic or other tangible material containing Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company and to my work, and will not take or keep in their possession any of the foregoing or any copies.  
xiii.Enforcement of Intellectual Property Rights. Executive will cooperate fully with the Company, both during and after their employment with the Company, with respect to the 
        12

procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related Developments. Executive will sign, both during and after their employment, all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development or Intellectual Property Rights therein.  If the Company is unable, after reasonable effort, to secure their signature on any such papers, Executive hereby irrevocably designates and appoints each officer of the Company as their agent and attorney-in-fact to execute any such papers on their behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development, including any Intellectual Property Rights therein.
xiv.Nonsolicitation and Noncompetition.  In order to protect the Company’s Proprietary Information and goodwill, during their employment and for a period of:  (i) one (1) year following the Date of Termination, or (ii) two (2) years following the Date of Termination if Executive breaches their fiduciary duty to the Company or if Executive has unlawfully taken, physically or electronically, property belonging to the Company (in either case the “Restricted Period”):
d.Executive shall not, directly or indirectly, in any manner, other than for the benefit of the Company, solicit or transact any business with any of the customers or customer prospects of the Company or any of its suppliers.  For purposes of this Agreement, (x) business shall include any business that researches, develops, manufactures, markets, sells or distributes a product or service that competes with a product or service of the Company, (y) customers shall include then current customers to which the Company provided products or services during the 12 months prior to the Date of Termination (the “One Year Lookback”) and customer prospects shall include customer prospects that the Company solicited during the One Year Lookback and that Executive had significant contact with or learned confidential information about in the course of their employment, and (z) suppliers shall include then current suppliers and suppliers that provided services to or in connection with the Company during the One Year Lookback.
e.Executive shall not, directly or indirectly, in any manner, solicit, entice or attempt to persuade any employee or consultant of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another entity, of any person who is then employed or engaged by the Company.  
f.Unless (y) the Company terminates Executive’s employment without Cause (as defined below) or Executive has been laid off; or (z) the Company waives the restrictions upon post-employment activities set forth in this Section 8(h)(iii), then, the Company shall make garden leave payments to Executive for the post-employment portion of the Restricted Period (but for not more than 12 months following the end of Executive’s employment) at the rate of 50% of the highest annualized base salary paid to Executive by the Company within the two-year period preceding the last 
        13

day of Executive’s employment (“Garden Leave Pay”), and in exchange, Executive shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, anywhere in the world, engage or otherwise participate in any business that develops, manufactures or markets any products, or performs any services, that are competitive with the products or services of the Company, including, without limitation, any products or services that target amino acid homeostasis for therapeutic and health purposes via the use of amino acid modalities; or products or services that the Company or its affiliates, has under development or that are the subject of active planning at any time during their employment. For purposes of this Section 8(h)(iii) only, and notwithstanding anything to the contrary in any other part of this Agreement or any other agreement between the Company and Executive, “Cause” shall mean a reasonable and good faith basis for the Company to be dissatisfied with Executive job performance, Executive’s conduct or Executive’s behavior. Executive acknowledges that this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. Executive further acknowledges and agrees that any payments Executive receives pursuant to this Section 8(h)(iii) shall reduce (and shall not be in addition to) any severance or separation pay that they are otherwise entitled to receive from the Company pursuant to this Agreement or otherwise.   
9.Litigation and Regulatory Cooperation.  During and after the Executive’s employment, the Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company.  The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company.  The Company shall reimburse the Executive for any reasonable outofpocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 9.
10.Government Contracts.  Executive acknowledges that the Company may have from time to time agreements with other persons or with the United States Government or its agencies that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Executive agrees to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under Section 8(e), Executive also assigns to the Company (or any of its nominees) all rights that Executive has or acquired in any Developments, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies.
        14

11.Prior Agreements. Executive hereby represents that, except as Executive has fully disclosed previously in writing to the Company, Executive is not bound by the terms of any agreement with any previous or current employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of their employment with the Company or to refrain from competing, directly or indirectly, with the business of such employer or any other party. Executive further represents that their performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by them in confidence or in trust prior to Executive’s employment with the Company. Executive will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others. 
12.Remedies Upon Breach.  Executive understands that the restrictions contained in Sections 8 and 9 of this Agreement (collectively, the “Continuing Obligations”) are necessary for the protection of the business and goodwill of the Company and Executive considers them to be reasonable for such purpose.  Any breach of the Continuing Obligations is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief, without the posting of a bond.  Executive further acknowledges that a court may render an award extending the Restricted Period as one of the remedies in the event of their violation of the Continuing Obligations.  If Executive violates the Continuing Obligations, in addition to all other remedies available to the Company at law (including, without limitation, the Company’s right to discontinue any payments Executive may receive pursuant to this Agreement), in equity, and under contract, Executive agrees that Executive is obligated to pay all the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and expenses. 
13.Use of Voice, Image and Likeness. During the Term, Executive gives the Company permission to use any and all of their voice, image and likeness, with or without using their name, in connection with the products and/or services of the Company, for the purposes of advertising and promoting such products and/or services and/or the Company, and/or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent prohibited by law.
14.No Employment Obligation.  Executive understands that this Agreement does not create an obligation on the Company or any other person to continue their employment.  Executive acknowledges that, unless otherwise agreed in a formal written employment agreement signed on behalf of the Company by an authorized officer, their employment with the Company is at will and therefore may be terminated by the Company or Executive at any time and for any reason, with or without cause.
15.Survival and Assignment by the Company.  Executive understands that the Continuing Obligations will continue in accordance with their express terms regardless of any changes in Executive’s title, position, duties, salary, compensation or benefits or other terms and conditions of employment.  Executive further understands that the Continuing Obligations will 
        15

continue following the termination of their employment regardless of the manner of such termination and will be binding upon their heirs, executors and administrators.  The Company will have the right to assign this Agreement to its affiliates, successors and assigns. Executive expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ Executive may be transferred without the necessity that this Agreement be resigned at the time of such transfer.
16.Notice of Resignation.  If Executive elects to resign from their employment with the Company, Executive agrees to provide the Company with written notification of their resignation at least thirty (30) days prior to their intended resignation date.  Such notice shall include information in reasonable detail about their post-employment job duties and other business activities, including the name and address of any subsequent employer and/or person or entity with whom or which Executive intends to engage in business activities during the Restricted Period and the nature of their job duties and other business activities. The Company may elect to waive all or part of the notice period in its sole discretion.   
17.Post-Employment Notifications.  During the Restricted Period, Executive will notify the Company of any change in their address and of each subsequent employment or business activity, including the name and address of their employer or other post-Company employment plans and the nature of their activities. 
18.Disclosures During Restricted Period.  Executive will provide a copy of this Agreement with all compensation terms redacted to any person or entity with whom Executive may enter into a business relationship, whether as an employee, consultant, partner, coventurer or otherwise, prior to entering into such business relationship during the Restricted Period only.
19.Waiver.  The Company and Executive acknowledge and agree that the Company’s election not to provide Executive with Garden Leave Pay as set forth in Section 8(h)(iii) shall be deemed a waiver of Executive’s noncompetition obligations under Section 8(h)(iii). Otherwise, no waiver of any of Executive’s obligations under this Agreement shall be effective unless made in writing by the Company. The failure of the Company to require Executive’s performance of any term or obligation of this Agreement, or the waiver of any breach of this Agreement, shall not prevent the Company’s subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
20.Severability.  In case any provisions (or portions thereof) contained in this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.  If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.     
21.Choice of Law and Jurisdiction.  This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted, 
        16

enforced and governed under the laws of the Commonwealth of Massachusetts. Executive hereby consents to personal jurisdiction of the state and federal courts situated within Massachusetts for purposes of enforcing this Agreement, and waive any objection that Executive might have to personal jurisdiction or venue in those courts, provided, however, the Company and Executive agree that all civil actions relating to Section 8 of this Agreement shall be brought in the county of Suffolk and that the superior court or the business litigation session of the superior court shall have exclusive jurisdiction.  ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT WITH THE COMPANY, INCLUDING WITHOUT LIMITAITON ANY CLAIMS OF DISCRIMINATION ARISING UNDER STATE OR FEDERAL LAW, WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF THE COMPANY AND THE EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF.  
22.Independence of Obligations.  Executive’s obligations under this Agreement are independent of any obligation, contractual or otherwise, the Company has to Executive.  The Company’s breach of any such obligation shall not be a defense against the enforcement of this Agreement or otherwise limit Executive’s obligations under this Agreement.   
23.Protected Disclosures.  Executive understands that nothing contained in this Agreement limits their ability to communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to the Company. Executive also understands that nothing in this Agreement limits their ability to share compensation information concerning them or others, except that this does not permit Executive to disclose compensation information concerning others that Executive obtains because their job responsibilities require or allow access to such information.
24.Defend Trade Secrets Act of 2016.  Executive understands that pursuant to the federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
25.Successor to the Executive.  This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.  In the event of the Executive’s death after their termination of employment but prior to the completion by the Company of all payments due them under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to their death (or to their estate, if the Executive fails to make such designation).
26.Successor to Company.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken 
        17

place.  Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.
27.Notices.  Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.
28.Counterparts.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.
29.Gender Neutral.  Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.  Plural pronouns shall be considered as including singular pronouns, male and female, unless the context clearly indicates otherwise.
Entire Agreement; Amendment.  This Agreement constitutes the entire agreement between the Company and Executive with respect to the subject matter hereof, and supersedes all prior agreements or understandings, both written and oral, between the Company and Executive with respect to the subject matter hereof, but does not in any way merge with or supersede any other confidentiality, assignment of inventions or other restrictive covenant agreement or obligation entered into by the Company and Executive, which agreements and obligations shall supplement, and shall not limit or be limited by, this Agreement.  This Agreement may be amended only in a written agreement executed by a duly authorized officer of the Company and Executive. 
IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.
AXCELLA HEALTH INC.
By: /s/ William Hinshaw 
        William Hinshaw
Its: President and Chief Executive Officer

By:      /s/ Andrew Suchoff 
            Andrew Suchoff

        18EX-10.12

 Exhibit 10.12 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

COLLABORATION AGREEMENT 

THIS COLLABORATION AGREEMENT (the “Agreement”) is made as of
October 3, 2017 (the “Effective Date”), by and between Project Chimera, Inc. a corporation organized and existing under the laws of Delaware, with its registered office located at 400 Technology Square, 10th Floor, Cambridge, MA 02139 (“Chimera”) and GLAXOSMITHKLINE INTELLECTUAL PROPERTY
DEVELOPMENT LIMITED, a corporation organized and existing under the laws of England and Wales, with its registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
(“GSK”). Each of Chimera and GSK may be referred to herein as a “Party” or together as the “Parties.” 

BACKGROUND 

WHEREAS, Chimera is a drug discovery company that is engaged in research and development across multiple
target areas for the purpose of designing and developing new therapeutically significant compounds for a broad range of diseases; 

WHEREAS, GSK is a pharmaceutical company with specialized experience in, among other things, discovery,
clinical development and commercialization of pharmaceutical products; and 
 WHEREAS, the Parties wish
to enter into a novel collaboration to jointly identify, research, and conduct preclinical development of Collaboration Compounds against specified Collaboration Targets to identify drug candidates (capitalized terms defined below). 

Now, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth
below, and for other good and valuable consideration, the receipt of which is hereby acknowledged, Chimera and GSK hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 The
following initially capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly): 
 1.1
“Additional Collaboration Target” has the meaning given in Section 2.3(a). 
 1.2
“Affiliate” means, as to a given entity, another entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such first entity. For purposes of this definition,
“control” with respect to an entity, means the ownership of fifty percent (50%) or more of the voting securities entitled to elect the directors or management of the entity, or the actual power to elect or direct the management of the
entity. 
 1.3 “Agreement” has the meaning given in the preamble to this Agreement. 

 1.4 “Alliance Manager” has the meaning given in Section 3.5

 1.5 “Applicable Law(s)” means all applicable laws, statutes, rules, regulations, ordinances and other
pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, government or Regulatory Authority. Specifically, and without limiting the foregoing, Applicable Law(s)
includes the Foreign Corrupt Practices Act of 1977, as amended. 
 1.6 “Bankruptcy Code” has the meaning given
in Section 11.2(b). 
 1.7 “Business Day” means a day other than a Saturday or a Sunday on which banking
institutions in London, England and Boston, Massachusetts are open for business, but in any event excluding the nine (9) consecutive calendar days beginning on December 24th of a Calendar Year and continuing through January 1st of the next
Calendar Year. 
 1.8 “Calendar Quarter” means a period of three (3) consecutive months ending on the
last day of March, June, September, or December, respectively. 
 1.9 “Calendar Year” means a period of twelve
(12) consecutive months beginning on January 1 and ending on December 31. 
 1.10 “Chimera” has the meaning
given in the preamble to this Agreement. 
 1.11 “Chimera Background IP” means all Intellectual Property
Controlled by Chimera or its Affiliates (a) as of the Effective Date or (b) that arises after the Effective Date from activities separate and apart from the activities conducted in connection with this Agreement. 

1.12 “Chimera Indemnitees” has the meaning given in Section 9.1. 

1.13 “Chimera IP” has the meaning given in Section 6.3(b). 

1.14 “Chimera Ligase Binder Data” has the meaning given in Section 3.8. 

1.15 “Chimera Materials” means [***]. 

1.16 “Collaboration Compound” has the meaning given in Section 2.5(b). 

1.17 “Collaboration Data” has the meaning given in Section 3.3. 

1.18 “Collaboration Target” means (a) the Initial Collaboration Targets and (b) any Additional Collaboration
Targets. 
 1.19 “Collaboration IP” means [***]. 

1.20 “Combination Product” has the meaning given in Section 1.53. 

  
 2 

 1.21 “Commercialization” means all activities undertaken with
respect to a Product relating to manufacturing, marketing, promotion (including advertising and detailing), medical affairs activities, medical science liaison activities, sponsored product or continuing medical education activities, post-Regulatory
Approval clinical studies, (that are not required to obtain such Regulatory Approval), obtaining pricing and reimbursement approval, in each case with respect to such product, any importing, offering for sale, distribution and sale of such product,
identifying, screening, treating or diagnosing patients as potential users of such Product, and interacting with Regulatory Authorities regarding the foregoing. When used as a verb, “Commercialize” means to engage in Commercialization.

 1.22 “Compound” means any chemical compound, matter, structure or composition. 

1.23 “Confidential Information” has the meaning given in Section 7.1. 

1.24 “Confirmed Hit” has the meaning given in Section 2.5(a). 

1.25 “Control” means, with respect to any Intellectual Property, the possession (whether by ownership or license, but
other than pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party a license, sublicense or access to such Intellectual Property, without violating the terms of any agreement or other arrangement with any
Third Party, in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license or access. 

1.26 “Cover(s)(ed)(ing)” means, with respect to a particular item or method, any Patent and/or Know-How, that but for a license under or ownership right in such Patent and/or Know-How, the manufacture, use, offer for sale, sale, importation, duplication, distribution or
other exploitation of such item (or any other item used in the manufacture, use, offer for sale, sale, importation, duplication, distribution or other exploitation thereof) or the practice of such method (or the use of any item in the practice of
such method), would infringe any Patent and/or misappropriate any Know-How (assuming, in the case of pending patent applications, that such pending patent applications are considered issued patents) in any of
the countries of manufacture, use, offer for sale, sale, importation, duplication, distribution and/or other exploitation. 
 1.27
“CPR” has the meaning given in Section 12.2(b). 
 1.28 “Derivative Compounds” has the
meaning given in Section 2.5(b). 
 1.29 “Develop” or “Development” means, with respect
to a Product, activities relating to obtaining Regulatory Approval of any Product or manufacturing or developing manufacturing capabilities for any Product. Development includes, but is not limited to, pharmacology studies, biomarker studies,
toxicology studies, formulation of active pharmaceutical and other ingredients, manufacturing process development and scale-up (including bulk compound production), quality control, technical support,
pharmacokinetic studies, preclinical activities, clinical studies and regulatory affairs activities. 
 1.30 “Disclosing
Party” has the meaning given in Section 7.1. 
 1.31 “Dispute” has the meaning given in
Section 12.2 
 1.32 “DNA-Tag” means a [***]. 

  
 3 

 1.33 “DNA-Tagged
Compound” means a [***]. 
 1.34 “Dollar,” “dollar” or
“$” means the legal tender of the United States. 
 1.35 “Effective Date” has the meaning given in
the preamble to this Agreement. 
 1.36 “FDA” means the United States Food and Drug Administration, and any of its
successor agencies or departments. 
 1.37 “First Commercial Sale” means the first sale, for use or
consumption by the general public of Product in a country after all required Regulatory Approvals for commercial sale of Product have been obtained in such country. 

1.38 “Force Majeur” has the meaning given in Section 12.7. 

1.39 “Good Data Management Practices” has the meaning given in Section 13.1. 

1.40 “Good Laboratory Practices” or “GLP” means the then-current standards, practices
and procedures promulgated or endorsed by (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices, as may be amended from time to time as well as any Rules Governing Medicinal
Products in the European Community Vol. Ill, ISBN 92.825 9619-2 (ex - OECD principles of GLP), (ii) the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21
C.F.R. Part 58, and (iii) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time. 

1.41 “Grant Agreement” has the meaning given in Section 5.1. 

1.42 “GSK” has the meaning given in the preamble to this Agreement. 

1.43 “GSK Background IP” means all Intellectual Property Controlled by GSK or its Affiliates [***]. 

1.44 “GSK DNA-Tagged Compound(s)” means [***]. 

1.45 “GSK Indemnitees” has the meaning given in Section 9.2. 

1.46 “GSK IP” has the meaning given in Section 6.2(b). 

1.47 “GSK Information” has the meaning given in Section 3.3. 

1.48 “GSK Library(ies)” means [***]. 

1.49 “GSK Ligase Binder Data” has the meaning given in Section 3.8. 

1.50 “GSK Materials” means [***]. 

  
 4 

 1.51 “GSK Program Hit IP” means Intellectual Property Controlled by
GSK or its Affiliates that Covers any Program Hit. 
 1.52 “Indemnify” has the meaning given in Section 9.1.

 1.53 “IND” means an investigational new drug application, or similar application or submission to conduct human
clinical investigations, in each case that is filed with or submitted to a Regulatory Authority in conformance with the requirement of such Regulatory Authority, and any amendments thereto. 

1.54 “Initial Collaboration Targets” has the meaning given in Section 2.2. 

1.55 “Intellectual Property” shall mean the following and rights therein: (a) inventions whether or not reduced to
practice or embodied in one or more Patents; (b) Patents; (c) Know-How and the right in any jurisdiction to limit the use or disclosure thereof; (d) copyrights or similar rights in writings,
designs, mask works, or other works of authorship, and registrations or applications for registrations of copyrights in any jurisdiction; (e) trademarks and service marks (registered or unregistered), trade dress, trade names, and other names
and slogans embodying business or product goodwill or indications of origin, and all applications or registrations in any jurisdiction pertaining to the foregoing; and all goodwill associated therewith. 

1.56 “Know-How” means all technical information and know-how, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, methods of synthesis, compound library designs, methods, protocols, expertise and other technology
applicable to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions
incorporating or comprising them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions,
processes, formula, and expertise that, in each case, is not in the public domain. 
 1.57 “Knowledge” means
the actual knowledge of any of the executive officers of a Party. 
 1.58 “License Transaction” has the meaning given
in Section 2.8(b)(i). 
 1.59 “Linker” means [***]. 

1.60 “Losses” has the meaning given in Section 9.1. 

1.61 “Net Sales” means, with respect to a Product, the aggregate gross invoiced sales prices from sales of all units of
such Product sold by Chimera, its Affiliates and Sublicensees to independent Third Parties (other than a Sublicensee) after deducting: 

[***] 

  
 5 

 For purposes of this Section 1.61, “Combination Product” means a product that includes
a device for delivery or at least one active ingredient other than a Product. 
 1.62
“Non-Publishing Party” has the meaning given in Section 7.7. 
 1.63
“Non-Selected Compounds” has the meaning given in Section 2.8(a)(iii). 

1.64 “Off-DNA Synthesis” means the de novo synthesis of Compounds [***].

 1.65 “Party” or “Parties” has the meaning given in the preamble to this Agreement. 

1.66 “Patent” means any patent application or patent anywhere in the world, including all of the following:
provisional, utility, divisional, continuation, continuation-in-part, and substitution applications; and utility, re-issue, re-examination, renewal and extended patents, and patents of addition, and any supplementary protection certificates or equivalent thereof anywhere in the world, restoration of patent terms and other similar rights.

 1.67 “Primary Binder Data” means [***]. 

1.68 “Prior CDA” means that certain Confidential Disclosure Agreement by and between Chimera and GSK dated
June 10, 2016, as amended. 
 1.69 “Prior MTA” means that certain Material Transfer Agreement by and between
Chimera and GSK dated October 19, 2016, as amended. 
 1.70 “Product” means [***]. 

1.71 “Program Hit” means a [***] but which has not otherwise been modified. 

1.72 “Project Team” has the meaning given in Section 3.1. 

1.73 [***] 
 1.74
“Publishing Party” has the meaning given in Section 7.7. 
 1.75 “Receiving Party” has the
meaning given in Section 7.1. 
 1.76 “Regulatory Approval” means, with respect to a country or extra-national
territory, any and all approvals (including NDAs), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some or all of such extra-national
territory. For the sake of clarity, Regulatory Approval shall not be achieved for a product in a country until all applicable pricing and governmental Third Party reimbursement approvals have also been obtained in such country. 

  
 6 

 1.77 “Regulatory Authority” means the FDA or any counterpart of the
FDA outside the United States. 
 1.78 “Representatives” means a Party’s or its Affiliates’ employees,
directors, officers, consultants and agents. 
 1.79 “Research Collaboration” has the meaning given in
Section 2.1. 
 1.80 “Research Collaboration Term” means, as determined on a Collaboration Compound-by-Collaboration Compound basis, the period commencing on the Effective Date and continuing until the earlier of (a) the expiry of GSK’s first right of
negotiation to such Collaboration Compound or Product and (b) the termination of this Agreement. 
 1.81 “Research
Plan” means the research plan for the Collaboration Targets attached hereto as Exhibit B, as such plan may be amended and updated from time to time as mutually agreed by the Project Team in accordance with the terms of this
Agreement. 
 1.82 “Scientific Advisor” has the meaning given in Section 3.6. 

1.83 “Scientific Liaison” has the meaning given in Section 3.2. 

1.84 “Screening Hit(s)” means [***]. 

1.85 “Screening Hit Criteria” means the properties as described in the Research Plan in Exhibit B
mutually agreed by Chimera and GSK as sufficient to identify a compound as a Screening Hit with regards to the applicable Collaboration Target. 

1.86 “Sublicensee” means any Third Party to which a Party has granted a sublicense in accordance with Section 2.7
or Section 4.4; but in each case excluding any Third Party acting solely as a distributor. 
 1.87 “Target”
means a biological target including a protein, peptide, nucleic acid, lipid, carbohydrate, or complex comprising any combination thereof. 

1.88 “Target Nomination Period” has the meaning given in Section 2.3(a). 

1.89 “Term” has the meaning given in Section 11.1. 

1.90 “Third Party” means any person or entity other than the Parties and their Affiliates. 

1.91 “Third Party Claims” has the meaning given in Section 9.1. 

  
 7 

 1.92 “Third Party Encumbrance” means with respect to a Target,
[***]. 
 1.93 “Third Party Protein Degradation Company” has the meaning given in Section 4.3(d). 

1.94 “Validation Testing” has the meaning given in Section 2.5(a). 

1.95 “Withholding Party” has the meaning given in Section 5.8. 

ARTICLE 2 

COLLABORATION 
 2.1
Overview. Chimera and GSK desire and intend to work together to discover, characterize, and optimize Compounds contained in, or otherwise derived from, the GSK Libraries in accordance with the provisions of Articles 2 and 3 of this Agreement
(the “Research Collaboration”) during each Research Collaboration Term. 
 2.2 Initial Collaboration Targets.
Prior to the Effective Date, Chimera and GSK mutually agreed on those protein degradation Targets identified on Exhibit A attached hereto (the “Initial Collaboration Targets”) for research. Chimera and GSK further agree that
all activities undertaken under the Prior MTA on those protein degradation Targets identified on Exhibit A will be deemed to be part of the Research Collaboration and notwithstanding the performance of research prior to the Effective Date,
will be deemed as research activities undertaken during a Research Collaboration Term. 
 2.3 Selection of Additional Collaboration
Targets. 
 (a) Target Nomination. For a period of [***] after the Effective Date (the “Target Nomination
Period”), the Parties may mutually agree to name additional Targets in the Research Collaboration as a Collaboration Target, provided that [***] would be designated as Collaboration Targets in the Research Collaboration at any given time
(i.e., a Collaboration Target must be removed from Exhibit A, and shall thereafter no longer constitute a “Collaboration Target,” in order for a Target to be added to Exhibit A as an Additional Collaboration Target, and all
rights and obligations of the Parties to such removed Target shall terminate). If [***], such Target shall not be included as an “Additional Collaboration Target” under this Agreement. Additional Collaboration Targets will be added
to Exhibit A by way of an amendment to this Agreement. 

  
 8 

 (b) Target Confidentiality. For the avoidance of doubt: (i) the fact that
Chimera has identified a Target as a potential Collaboration Target shall be the Confidential Information of Chimera and subject to the obligations and exemptions of ARTICLE 7 of this Agreement and (ii) the fact that a Target could not be
included as an Additional Collaboration Target [***] shall be the Confidential Information of GSK and subject to the obligations and exemptions of ARTICLE 7. 

2.4 Screening Hits and Program Hits. In the event that an Additional Collaboration Target is added pursuant to Section 2.3(a),
Chimera and GSK shall mutually agree Screening Hit Criteria for such Additional Collaboration Target, after which Chimera will be solely responsible for providing GSK with the necessary purified protein reagents required for GSK to perform its
obligations regarding such Additional Collaboration Targets under this Section 2.4. Following the mutual agreement of the Screening Hit Criteria and receipt of necessary reagents from Chimera, GSK shall, all in accordance with the Research
Plan, (i) screen its GSK Libraries (or any portion thereof) against such Collaboration Target(s), (ii) analyze Primary Binder Data using its proprietary software and algorithms and (iii) share the results of such analysis (including a
list of Screening Hits (if any) for such Collaboration Target) with the Project Team, [***]. The Project Team will advise Chimera regarding which Screening Hits may be suitable for Off-DNA Synthesis as Program
Hits. GSK will provide the chemical structures for the Screening Hits identified against each Collaboration Target. GSK shall perform such screening activities with requisite care, skill and diligence, in accordance with Applicable Laws and industry
standards, and by individuals who are appropriately trained and qualified. 
 2.5 Confirmed Hits and Collaboration Compounds. 

(a) Chimera shall be responsible for performing Off-DNA Synthesis to generate Program Hits and
conducting validation and testing for activity of such Program Hits, which activities may include specificity or selectivity analyses or activity in a secondary assay, and any additional activities, all as described in the Research Plan
(collectively, “Validation Testing”), but would not involve optimization or other actions to change the structure of a Screening Hit, in order to support identification of one or more Program Hits that demonstrate in vitro
binding against the applicable Collaboration Target (such Program Hit, a “Confirmed Hit”). Chimera shall perform such Validation Testing with requisite care, skill and diligence, in accordance with Applicable Laws and industry
standards, and by individuals who are appropriately trained and qualified. 
 (b) On a Collaboration Target-by-Collaboration Target basis, Chimera may select, in its sole discretion, [***] (each, a “Collaboration Compound”). Nothing herein shall limit Chimera’s right to create and
generate modified forms of Collaboration Compounds or new Compounds based on the same chemical scaffold as a Collaboration Compound; provided that such modified forms of a Collaboration Compound and such new Compounds (collectively,
“Derivative Compounds”) shall be considered Collaboration Compounds for the purposes hereunder. 

  
 9 

 2.6 Development and Commercialization. Subject to GSK’s rights under
Section 2.8(b), Chimera shall have the sole right and responsibility for the Development, and Commercialization of Collaboration Compounds and Products, including decision-making authority and all funding for such activities. 

2.7 Subcontracting. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates or subcontractors to
perform part of its obligations under the Research Plan. Any Affiliate or subcontractor to be engaged by a Party to perform a Party’s obligations set forth in this Agreement shall meet the qualifications typically required by such Party for the
performance of work similar in scope and complexity to the subcontracted activity; provided that any Party engaging an Affiliate or subcontractor hereunder shall remain responsible and obligated for such activities and shall ensure
that any and all Know-How, Patents and other Intellectual Property arising or created by any such Affiliate or subcontractor in relation to the subcontracted work shall be assigned solely to and in the name of
the hiring Party hereunder, and that any such Affiliate or subcontractor shall have such obligation to assign all such rights in and to all Intellectual Property arising from subcontracted work to the subcontracting Party as part of the agreement by
which such subcontractor is engaged by a Party hereunder. 
 2.8 Exclusivity and Options 

(a) Exclusivity 
 (i)
Subject to the terms and conditions of this Agreement, on a Collaboration Target-by-Collaboration Target basis, beginning upon acceptance of a Target as a Collaboration
Target and continuing until the earlier of [***] after such acceptance and (ii) Chimera’s termination of the development program for such Collaboration Target in accordance with 11.2(c), GSK shall not, whether alone or in collaboration
with any of its Affiliates or any Third Party [***], other than in accordance with this Agreement. 
 (ii) Subject to the terms and
conditions of this Agreement, Chimera shall not, whether alone or in collaboration with any of its Affiliates, engage any Third Party provider of libraries comprising DNA-Tagged Compounds to discover or
identify compounds directed against any Collaboration Target unless GSK first screens such Collaboration Target and such screening does not identify any Confirmed Hits, or if Confirmed Hits were identified by GSK’s screening, Chimera opted not
to [***]; provided that this clause (ii) shall not apply to the following Initial Collaboration Targets: STAT3 [***]. 
 (iii)
Notwithstanding anything to the contrary herein, on a Collaboration Target-by-Collaboration Target basis, if no Confirmed Hits are identified for such Collaboration
Target, or if Confirmed Hits were identified by GSK and Chimera opted not to select [***], then neither Party nor their Affiliates would be restricted 

  
 10 

 
from pursuing (or, conversely, have any obligations to pursue) research and Development with respect to such Collaboration Target or any other Target. If a Confirmed Hit is not selected by
Chimera as a Collaboration Compound (“Non-Selected Compound(s)”), such Non-Selected Compound will no longer be considered a Program Hit or Confirmed Hit
hereunder, Chimera’s license under Section 4.1(a) would terminate, and nothing in this Agreement will be deemed to grant Chimera any rights in or to such Non-Selected Compounds. 

(b) Options 
 (i) Right
of First Negotiation. In the event that Chimera and/or its Affiliates desires to collaborate with or grant a license or similar rights to any Third Party to research, Develop or Commercialize any Collaboration Compounds, Chimera shall notify
GSK, in writing prior to providing a term sheet to any Third Party for any such Collaboration Compound, and such notice shall set forth the structure and scope of such proposed transaction (a “License Transaction”) and shall
summarize the relevant data generated to date for such Collaboration Compound. GSK shall have the right, but not the obligation, to submit, [***] following such notice from Chimera, a written offer to Chimera summarizing GSK’s key terms and
conditions for such License Transaction. If such written offer is provided by GSK, the Parties will conduct non-exclusive, bona fide negotiations for a [***] following Chimera’s receipt of such
written offer from GSK, unless such period is extended by mutual written agreement of the Parties. Chimera shall have no obligation to accept the offer originally submitted by GSK or to accept any further offer which may be presented by GSK during
the period of bona fide negotiations, or to enter into any License Transaction with GSK, provided that, for a period of [***] after the period of bona fide negotiations Chimera shall not offer terms to a Third Party that are materially
less favorable to Chimera than those last offered to GSK. If the Parties do not enter into a License Transaction during such [***], then GSK’s rights under this Section 2.8(b)(i) will terminate with respect to such Collaboration Compounds.

 (ii) Conclusion of First Right of Negotiation. Notwithstanding Section 2.7(b)(i), if [***] prior to initiation of [***] in
relation to such Collaboration Compounds, Chimera has not yet entered into a Licensing Transaction with respect to any Collaboration Compounds or Products (meaning that Chimera retains rights to research, Develop or Commercialize any Collaboration
Compounds or Products), and Chimera desires to collaborate with or grant a license or similar rights to any Third Party with respect to any such Collaboration Compounds or Products, then Chimera shall so notify GSK, in writing, prior to providing a
term sheet to any Third Party for any such Collaboration Compound, and such notice shall set forth the structure and scope of such proposed License Transaction and summarize the relevant data generated to date for such Collaboration Compound. GSK
shall have the right, but not the obligation, to submit, within [***] following such notice from Chimera, a written offer to Chimera summarizing GSK’s key terms and conditions for such License Transaction. If such written offer is provided by
GSK, the Parties will conduct non-exclusive, bona fide negotiations for a maximum of [***] following Chimera’s receipt of such written offer from GSK unless such period is extended by mutual
written agreement of the Parties. Chimera shall have no obligation to accept the offer originally submitted by GSK or to accept any further offer which may be presented by GSK during the period of bona fide negotiations, or to enter into any
License Transaction with GSK, provided that, for a period of [***] after the period of bona fide negotiations Chimera shall not offer terms to a Third Party that are materially less favorable to Chimera than those last offered to GSK. If the
Parties do not enter into a License Transaction during such [***] period, then GSK’s rights under this Section 2.8(b)(ii) will terminate with respect to such Collaboration Compounds. 

  
 11 

 (iii) The foregoing rights of negotiation pursuant to this Section 2.8 will not apply
to [***]. 
 2.9 Materials. 

(a) Use of GSK Materials. Chimera shall not use GSK Materials in any way other than in accordance with the licenses granted herein,
including without limitation, in connection with conducting research, Development and Commercialization activities with respect to the Screening Hits, Program Hits, Confirmed Hits, Collaboration Compounds and Products for the applicable
Collaboration Target. 
 (b) Use of Chimera Materials. GSK shall not use Chimera Materials in any way other than to perform GSK’s
obligations under this Agreement. Except as expressly permitted under this Agreement, GSK shall not transfer the Chimera Materials to any Third Parties or outside of GSK. 

(c) Material Transfer Record. Such transfers shall be recorded using the material transfer record form set out in Exhibit C, which shall
be completed by the transferring party, submitted to the receiving party for countersignature by the Scientific Liaison prior to the transfer of Chimera Materials or GSK Materials, as applicable. 

2.10 Costs of Collaboration Efforts. Each Party shall be solely responsible for the costs of its own activities under the Research Plan,
and Chimera will be solely responsible for the costs of its additional research, Development and Commercialization of Program Hits and Products for Collaboration Targets. 

ARTICLE 3 

COMMUNICATION WITHIN THE RESEARCH COLLABORATION 

3.1 Project Team. The Parties shall establish and convene a project team (the “Project Team”), which shall be
responsible for the management of the day-to-day activities conducted under the Research Collaboration as more fully described in this Section 3.1. 

(a) Membership. The Project Team shall include the Chimera Scientific Liaison and the GSK Scientific Liaison, and any number of additional
Representatives of GSK and Chimera as may be mutually agreed between the Parties. Each Party shall provide the other with a list of its initial members of the Project Team as soon as possible (but no later than [***]) following the Effective Date.
Each Representative of a Party shall have sufficient seniority and expertise to participate on the Project Team. 

  
 12 

 (b) Meetings. The Project Team shall meet as often as required during the Research
Collaboration Term, which shall be at least monthly or more or less frequently as the Parties via the Project Team mutually agree, at such places and times or by such means (including teleconferencing) as agreed by the Parties. Each Party will bear
all expenses it incurs in regard to participating in all meetings of the Project Team, including all travel and living expenses. 
 3.2
Scientific Liaisons. Each of Chimera and GSK shall designate a scientific liaison (“Scientific Liaison”) having appropriate scientific expertise with respect to conduct of the Research Plan to be the primary contact for such
Party as further described in this Section 3.2. The Scientific Liaisons shall be the primary points of contact for the Parties regarding the collaboration activities contemplated by this Agreement and shall be responsible for monitoring the
exchange of relevant information and Materials between the Parties as required for the performance of the Research Plan, which shall be carried out through the use of the Material Transfer Record Form in Exhibit C. The name and contact
information for each Party’s Scientific Liaison, as well as any replacement(s) chosen by a Party, in its sole discretion, from time to time, shall be promptly provided to the other Party. 

3.3 Information Sharing. During the Research Collaboration Term for a Collaboration Compound or, if earlier, until Collaboration Data
for a particular Collaboration Target are licensed or partnered with a Third Party, Chimera’s Scientific Liaison will make all material data generated by Chimera (i) under a Research Plan pertaining to such Collaboration Compound and
(ii) in relation to Collaboration Compounds and Products, including chemical structures (“Collaboration Data”), available to GSK and the Project Team through an e-data room or shared
portal. Collaboration Data will also be made available to GSK and the Project Team by way of summary slides and provision of a written summary, and will be considered the Confidential Information of Chimera. GSK will, at its discretion, provide
advice, support, theories, techniques and potential improvements to Chimera’s scientific research and product development activities with the Project Team (“GSK Information”). Each Party’s Scientific Liaison shall
alternate in being responsible for preparing and circulating minutes of each meeting of the Project Team, setting forth, inter alia, Collaboration Data and GSK Information shared at each meeting, an overview of the discussions at the meeting
and a list of any actions, decisions or determinations approved by the Project Team and a list of any issues to be resolved by the Project Team at a subsequent meeting. Such minutes shall be effective only after approval by both Parties in writing
(which may be by electronic mail). With the sole exception of specific items of the meeting minutes to which the members cannot agree and that are escalated to executive officers of the Parties, definitive minutes of all Project Team meetings shall
be finalized no later than [***] after the meeting to which the minutes pertain. 
 3.4 Data and Results. Each Party shall own and
retain all right, title and interest in all data, results (including screening results), reports and records arising from activities performed by its Representatives in performance of the activities hereunder. 

3.5 Alliance Managers. Each Party shall designate a representative with all necessary business skill and expertise as necessary to be
the primary contact for such Party as regards all business development and/or contract-related communications between the Parties for all matters in connection with this Agreement (an “Alliance Manager”). The name and contact
information for each Party’s Alliance Manager, as well as any replacement(s) chosen by a Party, in its sole discretion, from time to time, shall be promptly provided to the other Party. 

  
 13 

 3.6 Scientific Advisors. Commencing on the Effective Date, Chimera has a right to
request a scientific advisor with knowledge in the field of targeted protein degradation be named by GSK (a “Scientific Advisor”), subject to execution of a separate contract detailing the rights and obligations of such
Scientific Advisor. The Parties acknowledge that the scientific advisor agreement could obligate Scientific Advisor to provide at least [***] of services to Chimera per quarter, and such additional days as mutually agreed by Chimera and Scientific
Advisor. Furthermore, such scientific advisor agreement may include an obligation for the Scientific Advisor to devote his/her best efforts to provide the services as follows: (a) attending meetings of Chimera’s scientific advisors;
(b) performing the duties of such scientific advisors at such meetings, as established from time to time by the mutual agreement of Chimera and the Scientific Advisor and Chimera’s other scientific advisors, including without limitation
meeting with Chimera employees, consultants and Chimera’s other scientific advisors, reviewing goals of Chimera and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and
improvements in Chimera’s scientific research and product development activities; and (c) providing consulting services to Chimera at its request, including a reasonable amount of informal consultation over the telephone or otherwise as
requested by Chimera. 
 3.7 Reporting. On an annual basis, following the end of the Research Collaboration Term and continuing until
the first to occur of the following events as determined on a Collaboration Target by Collaboration Target basis: (i) the filing of the first NDA for a Product targeting such Collaboration Target and (ii) the cessation of all Development
with respect to all Products targeting such Collaboration Target, Chimera shall provide GSK with written reports summarizing in reasonable detail the material Development activities (e.g., filing of an IND, commencement of clinical trials, filing of
an NDA, etc.) undertaken by or on behalf of Chimera (including its Affiliates and Sublicensees) with respect to the Development of Collaboration Compounds and Products, and each such report will be considered the Confidential Information of Chimera.
Notwithstanding the foregoing, if Chimera enters into a License Transaction with respect to a Product targeting a given Collaboration Target, the foregoing reporting obligation will continue with respect to such Collaboration Target to the extent
not prohibited by the terms of such License Transaction, provided such terms are reasonably demonstrable to GSK. 
 3.8 Ligases. GSK
may, at its discretion, provide data relating to chemical matter resulting from its internal screens of ligases using GSK Libraries to Chimera, and Chimera, at its discretion, may elect to optimize such compounds. If the Parties agree to include
ligase binders in the Research Collaboration, a research plan would be agreed at that time, and work would be conducted in accordance with such pre-agreed research plan. Each Party would share all data,
including chemical structures, generated in relation to such ligase binders (“GSK Ligase Binder Data” and “Chimera Ligase Binder Data”, respectively) until the earlier of achievement of pre-agreed criteria or
termination of the research effort. 

  
 14 

 ARTICLE 4 

LICENSES; DEVELOPMENT & COMMERCIALIZATION 

4.1 Mutual Research Licenses. 

(a) To Chimera. Subject to the terms and conditions of this Agreement, during each Research Collaboration Term, GSK hereby grants to
Chimera a limited, royalty-free, nonexclusive, sublicenseable, non-transferable (except as set forth in Section 12.5) worldwide right and license (i) under GSK Program Hit IP (if any) and GSK’s
interest in any Collaboration IP (if any), and (ii) to use any GSK Materials, in each case (i) and (ii) solely to permit Chimera, directly or with and through a Third Party, to perform Chimera’s responsibilities under the Research
Plan. 
 (b) To GSK. Subject to the terms and conditions of this Agreement, during each Research Collaboration Term, Chimera hereby
grants to GSK a limited, royalty-free, nonexclusive, sublicenseable, non-transferable (except as set forth in Section 12.5), worldwide right and license (i) under the Chimera IP and Chimera’s
interest in any Collaboration IP (if any), and (ii) to use any Chimera Materials, in each case (i) and (ii) solely to permit GSK, directly or with and through a Third Party, to perform GSK’s responsibilities under the Research Plan.

 4.2 Development/Commercialization License. GSK hereby grants to Chimera an exclusive, worldwide, sub-licenseable (through multiple tiers and subject to Section 4.4) and transferable (pursuant to Section 12.5) license (A) under GSK’s interest in any GSK Program Hit IP (if any) and
Collaboration IP (if any) and (B) to use any GSK Materials, in each case to the extent necessary or reasonably useful to make, use, sell, offer for sale and import Collaboration Compounds and Products. 

4.3 Mutual Non-Exclusive Licenses. 

(a) To Chimera. 
 (i)
Subject to Section 4.3(d), GSK hereby grants to Chimera a royalty- free, non-exclusive, perpetual, sublicensable (through multiple tiers), non-transferable (except
as set forth in Section 12.5) worldwide right and license, under the GSK Information, to permit Chimera to perform internal research and development activities. 

(ii) Subject to Section 4.3(d), GSK hereby grants to Chimera a royalty- free, non-exclusive,
perpetual, sublicensable (through multiple tiers), non-transferable (except as set forth in Section 12.5) worldwide right and license, under GSK Ligase Binder Data to permit Chimera to perform internal
research, development and commercialization activities. 
 (b) To GSK. 

(i) Subject to Section 4.3(d), Chimera hereby grants to GSK a royalty- free, non-exclusive,
perpetual, sublicensable (through multiple tiers), non-transferable (except as set forth in Section 12.5) worldwide right and license, under any Collaboration Data, to permit GSK to perform internal
research and development activities. 

  
 15 

 (ii) Subject to Section 4.3(d), Chimera hereby grants to GSK a royalty- free, non-exclusive, perpetual, sublicensable (through multiple tiers), non-transferable (except as set forth in Section 12.5) worldwide right and license, under any Chimera
Ligase Binder Data to permit GSK to perform internal research, development and commercialization activities. 
 (c) As between Chimera and
GSK, ownership of all Intellectual Property made or developed solely or jointly by or on behalf of GSK and Chimera in the course of GSK or Chimera exercising its rights under the licenses set forth in Sections 4.3(a) and 4.3(b) shall be governed by
Article 6 of this Agreement. 
 (d) Notwithstanding the licenses granted above, neither Party will disclose, directly or indirectly, any
Collaboration Data, Chimera Ligase Binder Data or GSK Ligase Binder Data (including those of collaborators and Affiliates) to a Third Party Protein Degradation Company for a period of [***] or, if earlier, until such Collaboration Data, Chimera
Ligase Binder Data or GSK Ligase Binder Data are definitively licensed or partnered with GSK or a Third Party. For purposes of this provision, Third Party Protein Degradation Companies are private or public companies with a market cap of less
than [***]. 
 4.4 Permitted Sublicenses. Each Party shall have the right to grant sublicenses under the licenses granted to it under
Section 4.1 and Section 4.2 and Section 4.3, respectively, without the consent of the other Party. Each sublicense granted by a Party shall be subject to and consistent with the terms and conditions of this Agreement. Each Party shall
remain fully liable for the acts and omissions of, and for breach of this Agreement by, its respective Affiliate(s) and Sublicensees and Third Party service providers, including subcontractors. 

4.5 Retained Rights. Notwithstanding the licenses granted to Chimera pursuant to Section 4.1 and Section 4.2, without limiting
the generality of Section 4.6, and subject to Section 2.8(a)(i), GSK shall retain for itself and its Affiliates, an exclusive (subject to the license grants to Chimera under Section 4.1(a)), worldwide right to make and use Screening
Hits, Program Hits and Confirmed Hits solely for research purposes. For clarity, nothing herein shall require GSK to physically remove any Screening Hits from the GSK Libraries. 

4.6 No Implied Licenses. Except as explicitly set forth in this Agreement, neither Party grants to the other Party any license, express
or implied, under its Intellectual Property. 
 ARTICLE 5 

FINANCIAL TERMS 
 5.1
Equity Issuance. In partial consideration of the rights granted by GSK to Chimera hereunder, Chimera shall procure that Kymera Therapeutics, LLC shall issue to GSK or its nominated Affiliate pursuant, and subject in all respects, to a
mutually-agreed unit grant and restriction agreement in the form attached as Exhibit D (the “Grant Agreement”), Series A Preferred Units of Kymera Therapeutics, LLC, which shares equal at least four percent (4%) of the
capitalization of Kymera Therapeutics, LLC on a fully diluted basis as of the Effective Date. 

  
 16 

 5.2 Royalties. 

(a) Royalties and Rates. Subject to the terms and conditions of this Agreement, as partial consideration for the rights assigned or
granted to each Party pursuant to this Agreement, Chimera shall pay to GSK royalties on aggregate Net Sales, on a Product-by-Product and country- by-country basis, as follows: 
  

			
	 Aggregate Net Sales of

a Product in a Calendar Year
	  	Royalty Rate
	 [***]
	  	[***]
	 [***]
	  	[***]

 By way of example, in a given Calendar Year, if the aggregate annual worldwide Net Sales for a Product is
$[***]. 
 (b) Royalty Term. Royalties under Section 5.2(a) shall be payable on the Net Sales of a Product, on a Product-by-Product and country-by-country basis, beginning on First Commercial Sale of such
Product in such country and continuing for ten (10) years thereafter. 
 (c) Reports and Royalty Payments. For as long as royalties
are due under this Section 5.2, Chimera shall furnish to GSK a written report, within [***] after the end of each Calendar Quarter, showing the amount of Net Sales and royalty accrued during the most recently completed Calendar Quarter. Royalty
payments for the applicable Calendar Quarter shall be due at the same time as such written report is delivered by Chimera to GSK. Such written report shall include, at a minimum, the following information for the applicable Calendar Quarter, each
listed by Product, and by country of sale or intended use: (i) Net Sales; (ii) the basis for any adjustments to the royalty payable with respect to such Net Sales; (iii) the currency used and conversion rate to Dollars, if any, and
(iv) the total royalty amount due hereunder with respect to such Net Sales. 
 5.3 Records and Audits. Chimera shall keep, and
shall cause each of its Affiliates and Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of calculating all royalties and other amounts payable to GSK hereunder and ensuring Chimera’s compliance
hereunder. For the [***] following the end of the Calendar Year to which each shall pertain, such books and records of accounting (including those of Chimera’s Affiliates and Sublicensees, as applicable) shall be kept at each of their principal
place of business and shall be open for inspection and copying at reasonable times and upon reasonable notice by an independent certified accountant selected by GSK, and which is reasonably acceptable to Chimera, for inspecting the royalties and
other amounts due to GSK under this Agreement. In no event shall such inspections be conducted hereunder more frequently than once every [***]. Such accountant shall have executed and delivered to Chimera and its Affiliates and Sublicensees, as
applicable, a customary confidentiality agreement. The results of such inspection, if any, may be shared by the accountant with Chimera and GSK at either Party’s request, and shall be binding on both Parties. Any underpayments shall be paid by
Chimera within [***] of notification of the results of such inspection. Any overpayments shall be fully creditable against amounts payable in subsequent payment periods but otherwise shall not be reimbursed by GSK. GSK shall pay for any such
inspections, except that in the event there is any upward adjustment in aggregate royalties or other amounts payable for any Calendar Year shown by such inspection of more than [***], Chimera shall reimburse GSK for any reasonable out-of-pocket costs of such accountant or related to such inspection. 

  
 17 

 5.4 Currency Exchange. All payments to be made hereunder by Chimera to GSK shall be
computed and paid in Dollars. Conversion of sales recorded in local currencies to Dollars will be performed in a manner consistent with Chimera’s normal practices used to prepare its audited financial statements for external reporting purposes,
provided that such practices use a widely accepted source of published exchange rates and are in accordance with GAAP or IFRS, as applicable, and such practice is verified by an independent auditor. 

5.5 Payment Method. All payments due under this Agreement to GSK shall be made by electronic transfer in immediately available funds,
via either a bank wire transfer or an ACH (automated clearing house) mechanism or other means of electronic funds transfer as agreed by the Parties to an account designated by GSK. 

5.6 Late Payments. Any undisputed amounts owed by Chimera to GSK under this Agreement that are more than [***] past due from the invoice
date, as applicable, shall thereafter, to the extent permitted by Applicable Law, be subject to interest at an annual percentage rate of [***]. 

5.7 Blocked Payments. If, by reason of Applicable Laws, it becomes impossible or illegal for Chimera to transfer royalties or other
payments under this Agreement to GSK, Chimera shall promptly notify GSK. During any such period described above, Chimera shall deposit such payments in local currency in the relevant jurisdiction to the credit of GSK in a recognized banking
institution designated by GSK or, if none is designated by GSK within a period of [***], in a recognized banking institution selected by Chimera and identified in a written notice given to GSK. 

5.8 Taxes. Where any sum due to be paid to either Party hereunder is subject to any withholding or similar tax, the Parties shall use
their commercially reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation
agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the payor shall remit such withholding or similar tax to the appropriate government authority, deduct the
amount paid from the amount due to payee and secure and send to payee the best available evidence of the payment of such withholding or similar tax. If withholding or similar taxes are paid to a government authority, each Party will provide the
other such assistance as is reasonably required to obtain a refund of the withheld or similar taxes, or obtain a credit with respect to such taxes paid. In the event that a government authority retroactively determines that a payment made by a Party
to the other pursuant to this Agreement should have been subject to withholding or similar (or to additional withholding or similar) taxes, and such Party (the “Withholding Party”) remits such withholding or similar taxes to the
government authority, the Withholding Party will have the right (a) to offset such amount, including any interest and penalties that may be imposed thereon (except to the extent any such interest or penalties result from the negligence of the
Withholding Party) against future payment obligations of the Withholding Party under this Agreement, (b) to invoice the other Party for such amount (which shall be payable by the other Party within [***] of its receipt of such invoice) or
(c) to pursue reimbursement by any other available remedy. 

  
 18 

 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1 Ownership. Except as otherwise set forth in Sections 6.2 and 6.3 ownership of any Intellectual Property that arises out of the
performance of this Agreement shall be determined in accordance with the rules of inventorship under U.S. patent law. Subject to Article 4, if the Parties are joint owners of any Collaboration IP, the Parties, as joint owners, shall have such
rights, throughout the world, to the joint Collaboration IP as are provided under the laws of the United States and the State of Delaware to joint owners of intellectual property rights in the State of Delaware. 

6.2 GSK Materials and IP. 

(a) GSK Materials. All GSK Materials shall remain the exclusive property of GSK, subject to the rights and licenses granted herein. 

(b) GSK IP. Subject to the license grants to Chimera under this Agreement, as between the Parties, GSK shall own and retain all right,
title and interest in and to: (i) GSK Background IP and (ii) any improvement, modification or enhancement to the GSK Background IP, [***], and that does not claim, Cover, or relate to the use or composition of any Collaboration Compound(s)
(including any Derivative Compounds) or Product(s) ((i) and (ii), collectively “GSK IP”). To the extent that Chimera acquires any rights under GSK IP, Chimera hereby assigns, conveys, and transfers to GSK all of Chimera’s right
and title in any such GSK IP. 
 6.3 Chimera Materials and IP. 

(a) Chimera Materials. All Chimera Materials shall remain the exclusive property of Chimera, subject to the rights and licenses granted
herein. 
 (b) Chimera IP. Subject to the license grants to GSK under this Agreement, as between the Parties, Chimera shall own and
retain all right, title and interest in and to: (i) Chimera Background IP and (ii) any improvement, modification or enhancement to Chimera Background IP [***], and that does not claim, Cover or relate to the use or composition of any
Screening Hit, Program Hit or Confirmed Hit ((i) and (ii), collectively “Chimera IP”). To the extent that GSK acquires any rights under Chimera IP, GSK hereby assigns, conveys, and transfers to Chimera all of GSK’s right and
title in any such Chimera IP. 
 6.4 Employees and Consultants; Assignment of IP. 

(a) Each Party shall ensure that all of its employees and consultants (as well as employees and consultants of its Affiliates and
subcontractors) that are supporting the performance of its obligations or exercise of its rights under this Agreement shall have executed agreements assigning to such Party all Intellectual Property made during the course of and as the result of
their 

  
 19 

 
association with such Party with respect to the performance of activities under this Agreement, and obligating the individual upon request to sign any documents to confirm or perfect such
assignment and to cooperate in the preparation and prosecution of any Patents claiming or otherwise covering such inventions and obligating the individual to obligations of confidentiality and non-use
regarding Confidential Information on materially similar terms to those set forth in ARTICLE 7. Each Party shall provide copies of all such agreements referenced in the foregoing sentence, which may be redacted as reasonably necessary, to the other
Party at the request of the other Party. 
 (b) GSK shall, and shall cause its Affiliates and subcontractors to, execute and deliver such
additional documents, including, without limitation, any assignments, instruments, conveyances and assurances, and take such further actions as may be reasonably required to ensure that all right, title and interest in Chimera IP assigned to Chimera
pursuant to Section 6.3(b) is effectively transferred to and held by Chimera. Chimera shall, and shall cause its Affiliates and subcontractors to, execute and deliver such additional documents, including, without limitation, any assignments,
instruments, conveyances and assurances, and take such further actions as may be reasonably required to ensure that all right, title and interest in any GSK IP assigned to GSK pursuant to Section 6.2(b) is effectively transferred to and held by
GSK. 
 6.5 Disclosure. GSK shall promptly disclose to Chimera all Chimera IP invented or developed by Representatives of GSK
hereunder. Chimera shall promptly disclose to GSK all GSK IP invented or developed by Representatives of Chimera hereunder. 
 6.6 Further
Assurances. Each Party agrees to execute all such documents and instruments and to perform all such acts (and cause its Affiliates, and each of their relevant employees and agents, to execute such documents and instruments and to perform such
acts) as may be reasonably necessary in order to formally vest ownership as set forth in Section 6.2 and Section 6.3. 
 6.7
Patent Prosecution and Maintenance. Each Party shall have the sole right to control the preparation, prosecution and maintenance of patent applications and patents claiming inventions owned by such Party, at its sole expense. The Parties shall
establish a process for the control and funding of the preparation, prosecution and maintenance of patent applications and patents within any jointly owned Intellectual Property from time to time following the Effective Date as reasonably necessary
as agreed between the Parties. 
 6.8 Infringement of Patents by Third Parties. Each Party shall have the sole right to control the
enforcement of patent applications and patents claiming inventions owned by such Party, at its sole expense. The Parties shall establish a process for the control and funding of enforcement of patents within any jointly owned Intellectual Property
from time to time following the Effective Date as reasonably necessary as agreed between the Parties. 

  
 20 

 ARTICLE 7 

CONFIDENTIALITY; PUBLICITY 

7.1 General. “Confidential Information” means any and all information disclosed or submitted by one Party (in such
capacity, the “Disclosing Party”) to the other Party (in such capacity, the “Receiving Party”) in writing or in other tangible form, or if disclosed orally, that is indicated to be confidential at the time of
disclosure and confirmed in writing as such within [***] after initial disclosure to one Party by the other Party in connection with this Agreement. The GSK Libraries, GSK IP, GSK Program Hit IP, Screening Hits, Program Hits, Confirmed Hits, GSK
Ligase Binder Data and any GSK Materials shall be GSK’s Confidential Information. The Collaboration Targets, Collaboration Data, Collaboration Compounds (including Derivative Compounds), Chimera Ligase Binder Data, Chimera IP and any Chimera
Materials shall be Chimera’s Confidential Information. Except as otherwise permitted in the reasonable exercise of rights licensed herein (i) each Party shall receive and maintain the other Party’s Confidential Information in
strict confidence, but, in such case, still subject to applicable requirements of this Agreement, including, for example, Section 6.4(a), and (ii) neither Party shall disclose any Confidential Information of the other Party to any Third
Party. Neither Party shall use the Confidential Information of the other Party for any purpose other than as required to perform its obligations or in the reasonable performance of its obligations or exercise of its rights hereunder. Each Party, in
its capacity as a Receiving Party, agrees that it may disclose Disclosing Party’s Confidential Information to its and its Affiliates’ Representatives requiring access thereto for the purposes of this Agreement, provided, however,
that prior to making any such disclosures, each such Representative shall (a) be made aware of the confidential nature of such information, (b) be bound by written agreement or other similar obligation to maintain
Confidential Information in confidence and (c) shall be bound by obligations not to use such Confidential Information for any purpose other than as necessary to perform the Receiving Party’s obligations or exercise its rights under
this Agreement in accordance with the terms and conditions of this Agreement. Receiving Party agrees to take all reasonable steps to ensure that Disclosing Party’s Confidential Information shall be maintained in confidence including such steps
as it takes to prevent the disclosure of its own proprietary and confidential information of like character. Receiving Party shall take all steps necessary to ensure that its Affiliates and Representatives shall comply with the terms and conditions
of this Agreement, and each Party shall be responsible for breach of this ARTICLE 7 by its Affiliates and its and their respective Representatives. The foregoing obligations of confidentiality and non-use
shall survive, and remain in effect for a period of [***] after the termination or expiration of this Agreement. 
 7.2 Exclusions from
Nondisclosure Obligation. The nondisclosure and nonuse obligations in Section 7.1 shall not apply to any Confidential Information to the extent that Receiving Party can establish by competent written proof that: 

(a) at the time of disclosure is publicly known; 

(b) after disclosure, becomes publicly known by publication or otherwise, except by breach of this Agreement by Receiving Party; 

  
 21 

 (c) was in Receiving Party’s possession in documentary form at the time of disclosure
hereunder other than as a result of a prior confidential disclosure by Disclosing Party or its Affiliate under the terms of the Prior CDA or Prior MTA; 

(d) was received by Receiving Party from a Third Party who had the lawful right to disclose the Confidential Information and who shall not have
obtained the Confidential Information from Disclosing Party; or 
 (e) is independently developed by Receiving Party (i.e., without reference
to or reliance on Confidential Information of Disclosing Party). 
 Notwithstanding the foregoing: (i) the fact that certain technology becomes
publicly known shall not release a Party from the obligation to keep confidential (and not use) the information that such technology is practiced (or not practiced) by the other Party; and (ii) the fact that individual features or combinations
of features of a technology are or may become publicly known shall not be deemed to indicate that the overall combination is publicly known or disclosed and shall not allow the Party to whom individual features or combinations of features of a
technology was disclosed under this Agreement to disclose (or practice) such individual features or combinations of features of a technology outside the scope of a license granted to such Party under this Agreement. 

7.3 Required Disclosures. If either Party is required to disclose any Confidential Information of the other Party, pursuant to: a
governmental law, regulation or order, an order of a court of competent jurisdiction; if strictly necessary to defend litigation (meaning that the defense would not be possible if the information were not disclosed); if necessary to prosecute a
litigation under Section 6.8 or between the Parties to establish their rights under this Agreement; or to comply with the rules of the U.S. Securities and Exchange Commission or any stock exchange or listing entity, then Receiving Party may do
so; provided, however, that Receiving Party shall (i) give advance written notice to Disclosing Party, (ii) make a reasonable effort to assist Disclosing Party (at Disclosing Party’s request and expense) to obtain a protective
order requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation required, and (iii) use and disclose the Confidential Information solely to the extent required by the law, regulation,
order, or rule. 
 7.4 Terms of Agreement. The terms of this Agreement are the Confidential Information of both Parties; provided,
however, that (a) each Party shall be entitled to disclose the terms of this Agreement to bona fide actual or prospective acquirers, underwriters, investors, lenders or other financing sources (and counsel for the foregoing) and
(b) Chimera shall be entitled to disclose the terms of this Agreement to any bona fide potential sublicensee (and counsel for the foregoing) who, in the case of each of clauses (a) and (b), are obligated to keep such information
confidential. Moreover, each Party shall be entitled to disclose the terms of this Agreement to legal, financial, business and investment banking advisors to such Party, under legally binding obligations of confidentiality and non-use outside of their representation and/or advice to the Party. In addition, if legally required, a copy of this Agreement may be filed by either Party with the U.S. Securities and Exchange Commission (or
relevant ex-U.S. counterpart). In that case, the filing Party shall diligently seek confidential treatment for terms of this Agreement for which confidential treatment is reasonably available, and shall
provide the non-filing Party reasonable advance notice of the terms proposed for redactions and a reasonable opportunity to request that the filing Party make additional redactions to the extent confidential
treatment is reasonably available under the law. 

  
 22 

 7.5 Return of Confidential Information. Promptly after the termination or expiration
of this Agreement for any reason, each Party shall return to the other Party or destroy, as such other Party shall direct, all tangible manifestations of such other Party’s Confidential Information in the possession of the Receiving Party at
that time, and to which it does not have a license under Section 4.3, subject to the Receiving Party’s right to maintain one copy of such tangible manifestations of such other Party’s Confidential Information solely for purposes of
monitoring its compliance with this Agreement. 
 7.6 Publicity. Neither Party shall make any statements or releases regarding this
Agreement, the terms and conditions of this Agreement or the activities of the Parties hereunder without the prior written consent of the other Party. 

7.7 Publication. Chimera may publish results concerning Collaboration Compounds, including without limitation, results generated in the
performance of the Research Plan with respect to Program Hits that were subsequently selected by Chimera as Collaboration Compounds. Except as provided in the foregoing sentence, neither Party may, except with the other Party’s prior written
consent, publish any information generated under the Research Plan, provided that under no circumstances may the publishing party publish Confidential Information of the non-publishing Party. If a Party wishes
to disclose information generated under the Research Plan (the “Publishing Party”), the Publishing Party shall provide a copy of the proposed disclosure to the other Party (the
“Non-Publishing Party”) at least [***] prior to such proposed disclosure. The Non-Publishing Party shall notify the Publishing Party during such at
least [***] reviewing period whether consent is given, and if the publication or presentation of the Publishing Party includes Confidential Information of the Non-Publishing Party; in the latter case, the
Publishing Party shall remove such Confidential Information from such proposed publication or presentation. Authorship of all publications and presentations of data, results or information will be made in accordance with industry standards and
journal requirements. Each Party agrees to work in good faith with the other Party with respect to any such publication or presentation reasonably requested by such other Party. 

ARTICLE 8 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1 Mutual. Each of Chimera and GSK hereby represents and warrants that the representing and warranting Party is duly organized in its
jurisdiction of incorporation; that the representing and warranting Party has the full power and authority to enter into this Agreement; that this Agreement is binding upon the representing and warranting Party; that this Agreement has been duly
authorized by all requisite corporate action within the representing and warranting Party; and that the execution, delivery and performance by the representing and warranting Party of this Agreement and its compliance with the terms and conditions
hereof does not result in a breach of any of the terms and conditions of or constitute a default under (a) any agreement or other instrument binding or affecting it or its Affiliate or the property of either of them, (b) the provisions of
its bylaws or other governing documents or (c) any order, writ, injunction or decree of any governmental authority entered against it or by which any of its property is bound. 

  
 23 

 8.2 GSK. GSK hereby: 

(a) As of the Effective Date, represents and warrants that, to GSK’s Knowledge, the performance by GSK or an Affiliate of GSK of the
activities assigned to GSK under the Research Plan will not infringe the patent rights of any Third Party and will not misappropriate any trade secret of any Third Party. 

(b) As of the Effective Date, represents and warrants that GSK and its Affiliates are not debarred and do not Knowingly employ or otherwise use
in any capacity the services of any person that is or has been the subject of debarment or exclusion proceedings by a Regulatory Authority, including debarment proceedings under subsection 306(a) or (b) of the Generic Drug Enforcement Act of
1992. If at any time GSK, its Affiliates or any such persons become debarred, GSK shall promptly notify Chimera of such fact. 
 (c) GSK
represents and warrants that GSK and its Affiliates have not assigned, transferred, conveyed, exclusively licensed, or otherwise encumbered its or its Affiliates’ right, title and interest in any [***] as of the Effective Date in any manner
that would prevent GSK and its Affiliates from granting the licenses and rights to Chimera and its Affiliates under this Agreement. 
 (d)
GSK hereby covenants that GSK and its Affiliates shall not enter into any agreement, that would (i) conflict or interfere with the licenses and other rights granted to Chimera and its Affiliates under this Agreement or (ii) otherwise
restrict the ability of the Parties to perform their obligations under this Agreement. 
 (e) GSK hereby covenants that GSK and its
Affiliates will not assign, transfer, convey, exclusively license, or otherwise encumber its or its Affiliates’ right, title and interest in [***] as of the Effective Date in any manner that would prevent GSK and its Affiliates from granting
the licenses and rights to Chimera and its Affiliates under this Agreement 
 8.3 Chimera. Chimera hereby: 

(a) As of the Effective Date, represents and warrants that, to Chimera’s Knowledge, the performance by Chimera or an Affiliate of Chimera
of the activities assigned to Chimera under the Research Plan will not infringe the patent rights of any Third Party and will not misappropriate any trade secret of any Third Party. 

(b) As of the Effective Date, represents and warrants that Chimera and its Affiliates are not debarred and do not Knowingly employ or otherwise
use in any capacity the services of any person that is or has been the subject of debarment or exclusion proceedings by a Regulatory Authority, including debarment proceedings under subsection 306(a) or (b) of the Generic Drug Enforcement Act
of 1992. If at any time Chimera, its Affiliates or any such persons become debarred, Chimera shall promptly notify GSK of such fact. 

  
 24 

 (c) Chimera represents and warrants that Chimera and its Affiliates have not assigned,
transferred, conveyed, exclusively licensed, or otherwise encumbered its or its Affiliates’ right, title and interest in any Collaboration Data as of the Effective Date in any manner that would prevent Chimera and its Affiliates from granting
the licenses and rights to GSK and its Affiliates under this Agreement. 
 (d) Chimera hereby covenants that Chimera shall not, and shall
cause its Affiliates not to, enter into any agreement, that would (i) conflict or interfere with the licenses and other rights granted to GSK and its Affiliates under this Agreement or (ii) otherwise restrict the ability of the Parties to
perform their obligations under this Agreement. 
 (e) Chimera hereby covenants that Chimera and its Affiliates will not assign, transfer,
convey, exclusively license, or otherwise encumber its or its Affiliates’ right, title and interest in any Collaboration Data as of the Effective Date in any manner that would prevent Chimera and its Affiliates from granting the licenses and
rights to GSK and its Affiliates under this Agreement. 
 8.4 DISCLAIMER OF WARRANTIES. OTHER THAN THE EXPRESS WARRANTIES OF SECTIONS
8.1, 8.2 and 8.3, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT ANY PRODUCTS DEVELOPED UNDER THIS AGREEMENT ARE FREE FROM THE
RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE, OR THAT ANY PATENTS WILL ISSUE OR BE VALID OR ENFORCEABLE, OR THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL.

 ARTICLE 9 

INDEMNIFICATION 
 9.1
By GSK. GSK hereby agrees to indemnify, defend and hold harmless (collectively, “Indemnify”) Chimera, its Affiliates and its and their Representatives (collectively, “Chimera Indemnitees”) from and against any
and all claims, demands, actions, suits and proceedings brought by a Third Party (collectively, “Third Party Claims”), and all liability, loss, damage or expense (including, without limitation, reasonable attorneys’ fees)
(collectively, “Losses”) finally awarded or agreed to as a settlement of such Third Party Claims, in each case to the extent such Third Party Claims arise out of or result from (a) the gross negligence or willful misconduct of
any GSK Indemnitee in the performance of its obligations under this Agreement or (b) GSK’s breach of its warranties or representations under this Agreement; except in each case of (a) and (b) to the extent that a Third Party Claim
arises out of or results from the gross negligence or willful misconduct of any Chimera Indemnitee or Chimera’s breach of its warranties or representations under this Agreement. 

  
 25 

 9.2 By Chimera. Chimera hereby agrees to Indemnify GSK, its Affiliates and its and
their Representatives (collectively, “GSK Indemnitees”) from and against any and all Third-Party Claims, and all Losses finally awarded or agreed to as a settlement of such Third-Party Claims, in each case to the extent such Third
Party Claims arise out of or result from (a) the gross negligence or willful misconduct of any Chimera Indemnitee in the performance of its obligations under this Agreement; (b) Chimera’s breach of its warranties or representations
under this Agreement; or (c) the Development and Commercialization of Collaboration Compounds and Products by Chimera and its Affiliates, and its and their respective licensees and commercial partners; except in each case of (a), (b) and
(c) to the extent that a Third-Party Claim arises out of or results from the gross negligence or willful misconduct of any GSK Indemnitee or GSK’s breach of its warranties or representations under this Agreement. 

9.3 Procedures. Each of the foregoing agreements to Indemnify is conditioned on the relevant Chimera Indemnitees or GSK Indemnitees
(a) providing the Party that is obligated to indemnify prompt written notice of any Third Party Claim giving rise to an indemnification obligation hereunder, provided, that the failure to promptly provide such notice shall not relieve the
indemnifying Party of its obligations except, and only to the extent, that the indemnifying Party is actually prejudiced as a result of such failure, (b) permitting the indemnifying Party to assume full responsibility to investigate, prepare
for and defend against any such Third Party Claim, provided that the indemnified Party shall be entitled to participate in, but not control, the defense of a Third Party Claim and to engage counsel of its choice for such purpose at its own cost; and

 (a) providing reasonable assistance in the defense of such Third Party Claim at the indemnifying Party’s request and reasonable
expense. The indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Third Party Claims, on such terms as the indemnifying Party in its reasonable discretion, shall
deem appropriate (provided, however, that such terms must (i) include a complete and unconditional release of the indemnified Party from all liability with respect thereto and (ii) not include any admission of fault by, or impose any
liability or obligation (other than the payment of money which shall be satisfied by the indemnifying Party) on, the indemnified Party; in each case of (i) and (ii) with the prior written consent of the indemnified Party (such consent not to be
unreasonably withheld, conditioned or delayed). 
 ARTICLE 10 

LIABILITY 
 10.1
Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY DAMAGES THAT ARE NOT A DIRECT AND FORESEEABLE CONSEQUENCE OF THE BREACH, ACTION OR OMISSION GIVING RISE TO A CLAIM HEREUNDER (FOR EXAMPLE, ANY INDIRECT, CONSEQUENTIAL,
EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING DAMAGE TO GOODWILL), INCLUDING WITHOUT LIMITATION, CLAIMS ARISING UNDER ARTICLE 9 OF THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 10.1 IS INTENDED TO OR SHALL LIMIT OR RESTRICT
DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTIONS 7.1 - 7.5. 
 10.2 Liability Cap. Except as provided in
ARTICLE 9, neither Party shall be liable (whether in contract, tort or otherwise) to the other Party for an amount greater than [***]. 

  
 26 

 ARTICLE 11 

TERM AND TERMINATION 

11.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or
by mutual written consent, shall continue on a Product-by-Product and country-by-country
basis, until there are no more royalty payments owed to GSK on any Products in any country pursuant to this Agreement (the longest such period of time for any Product hereunder, the “Term”). Upon there being no more such payments
hereunder for any Product in any country, the licenses granted to Chimera pursuant to Section 4.2 shall become fully paid up, perpetual, irrevocable licenses with respect to all Products in all countries. 

11.2 Termination. 
 (a)
Material Breach. Either Party may terminate this Agreement for the material breach of this Agreement by the other Party, if such breach (other than non-payment of amounts owed) remains uncured [***]
days following notice from the non-breaching Party to the breaching Party specifying such breach. If there is a good faith dispute as to the existence or cure of a breach or default pursuant to this
Section 11.2, all applicable cure periods shall be tolled during the existence of such good faith dispute and no termination for a breach which is disputed in good faith shall become effective until such dispute is resolved pursuant to the
process set forth in Section 12.2. 
 (b) Bankruptcy. If, at any time during the Term (i) a case is commenced by or against
either Party under Title 11, United States Code, as amended, or analogous provisions of applicable law outside the United States (the “Bankruptcy Code”) and, in the event of an involuntary case under the Bankruptcy Code, such case
is not dismissed within [***] after the commencement thereof, (ii) either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (iii) either
Party assigns all or a substantial portion of its assets for the benefit of creditors, (iv) a receiver or custodian is appointed for either Party’s business, or (v) a substantial portion of either Party’s business is subject to
attachment or similar process; then, in any such case ((i), (ii), (iii), (iv) or (v)), the other Party may terminate this Agreement upon written notice to the extent permitted under applicable law. 

(c) Convenience. Either Party may terminate this Agreement in its entirety for any or no reason upon [***] prior written notice to the
other Party. 
 11.3 Effect of Termination. 

(a) Termination for Convenience. If either Party terminates this Agreement in its entirety pursuant to Section 11.2(c), then, the
following shall occur: 
 (i) the Parties’ respective obligations under the Research Plan shall terminate; 

  
 27 

 (ii) the terminating Party’s obligations under Section 2.8(a) would survive such
termination for the remainder of the applicable exclusivity period and the nonterminating Party’s obligations under Section 2.8(a) would end; 

(iii) the licenses granted to Chimera under Section 4.2 shall survive such termination for all Collaboration Compounds that have been
selected in accordance with Section 2.5 as of the effective date of termination and no other Compounds shall be eligible for selection as Collaboration Compounds as of such date; 

(iv) the licenses granted to each of Chimera and GSK under Section 4.3 as of the effective date of termination shall survive; and 

(v) the Parties’ rights and obligations under Sections 5.2 - 5.8 (inclusive) shall remain in full force and effect with respect to all
Collaboration Compounds and all Products, including without limitation, Chimera’s obligation to pay royalties to GSK as set forth in Article 5. 

(b) Termination by GSK for Material Breach. If GSK terminates this Agreement in its entirety pursuant to Section 11.2(a) as a
result of Chimera’s uncured material breach, then the following shall occur: 
 (i) the Parties’ respective obligations under the
Research Plan shall terminate; 
 (ii) Chimera’s obligations under Section 2.8(a) would survive such termination for the remainder
of the applicable exclusivity period and GSK’s obligations under Section 2.8(a) would terminate; 
 (iii) the licenses granted to
Chimera under Section 4.2 shall survive such termination for all Collaboration Compounds that have been selected in accordance with Section 2.5 as of the effective date of termination and no other Compounds shall be eligible for selection
as Collaboration Compounds as of such date; provided however, that, solely in the event that this Agreement is terminated by GSK pursuant to Section 11.2(a) for an uncured material breach by Chimera of its obligations under Articles 14, 15 or
16, then, as of the effective date of termination of this Agreement, (i) the licenses granted to Chimera under Section 4.2 shall terminate with respect to all Collaboration Compounds (including all Collaboration Compounds that have been
selected in accordance with Section 2.5 as of the effective date of termination) and (ii) notwithstanding anything herein to the contrary, the payment obligations set forth in Article 5 and Sections 11.3(b)(iv) and 11.3(b)(v) shall
terminate and be of no further force or effect; 
 (iv) except as otherwise provided in Section 11.3(b)(iii), the Parties’ rights
and obligations under Sections 5.2 - 5.8 (inclusive) shall remain in full force and effect with respect to all Collaboration Compounds and all Products, including without limitation, Chimera’s obligation to pay royalties to GSK as set forth in
Article 5; and 
 (v) [***]. 

  
 28 

 (c) Termination by Chimera for Material Breach. If Chimera terminates this Agreement
in its entirety pursuant to Section 11.2(a) as a result of GSK’s uncured material breach, then, the following shall occur: 
 (i)
the Parties’ respective obligations under the Research Plan shall terminate; 
 (ii) GSK’s obligations under Section 2.8(a)
would survive such termination for the remainder of the applicable exclusivity period, and Chimera’s obligations under Section 2.8(a) would terminate; 

(iii) the licenses granted to Chimera under Section 4.2 shall survive such termination for all Collaboration Compounds that have been
selected in accordance with Section 2.5 as of the effective date of termination and no other Compounds shall be eligible for selection as Collaboration Compounds as of such date; 

(iv) the licenses granted to each of Chimera and GSK under Section 4.3 as of the effective date of termination shall survive; and 

(v) the Parties’ rights and obligations under Sections 5.2-5.8 (inclusive) shall remain in full
force and effect with respect to all Collaboration Compounds and all Products, including without limitation, Chimera’s obligation to pay royalties to GSK as set forth in Article 5; provided that, [***] and payment of such reduced amount shall
be deemed to be payment in full by Chimera. 
 11.4 Survival in All Cases. Termination of this Agreement shall be without prejudice to
or limitation of any other remedies available to nor any accrued obligations of either Party. In the event this Agreement expires or is terminated in accordance with Section 11.2, all rights and obligations under this Agreement shall
immediately cease, except that the Parties’ respective rights and obligations under Articles 1 (as applicable), 6, 7, 9 and 10, and Sections 4.3(a), 4.3(b), 8.4, 11.3, 11.4, 11.5, 12.2, 12.3, 12.8, 12.9, 12.10, 12.13, 12.14 and 12.15 shall
survive any expiration or termination of this Agreement. 
 11.5 Bankruptcy. All licenses and rights to licenses granted under or
pursuant to this Agreement by a Party to the other Parties are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. The Parties agree that each Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its respective rights and elections under the Bankruptcy Code. A Party (in
any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the exercise by a Party as a licensee
of rights under this Agreement, or its Affiliates, of its rights and licenses to such intellectual property in accordance with this Agreement. The foregoing provisions are without prejudice to any rights a Party may have arising under the Bankruptcy
Code or other applicable law. 

  
 29 

 ARTICLE 12 

MISCELLANEOUS 
 12.1
Independent Contractors. The Parties shall perform their obligations under this Agreement as independent contractors. Nothing contained in this Agreement shall be construed to be inconsistent with such relationship or status. This Agreement and
the Parties’ relationship in connection with it shall not constitute, create or in any way be interpreted as a joint venture, fiduciary relationship, partnership or agency of any kind. 

12.2 Dispute Resolution. 

(a) Resolution by Executive Officers. The Parties agree that the procedures set forth in this Section 12.2 and Section 12.3
shall be the exclusive mechanism for resolving any dispute, controversy, or claim (each, a “Dispute”) between the Parties that may arise from time to time pursuant to this Agreement relating to any Party’s rights and/or
obligations. Except as otherwise provided in this Agreement, in the event of any Dispute between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either Party hereunder, the Parties
shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within [***], either Party may, by written notice to the other Party,
refer the Dispute to the executive officers designated by the Parties for attempted resolution. Such officers, or their designees, shall attempt in good faith to promptly resolve such Dispute within [***] thereafter. In the event that any matter is
not resolved under the foregoing provisions, each Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2(b). 

(b) Mediation. If a Dispute arises out of or relating to this Agreement, or the breach thereof, and if said Dispute is not resolved
through negotiation by the Parties under Section 12.2(a), the Parties agree that they shall attempt in good faith to resolve the Dispute by referring it for confidential mediation under the fast track mediation rules of procedure of the
International Institute for Conflict Prevention & Resolution (the “CPR”) in effect at the start of mediation. Unless otherwise agreed, the Parties shall select a mediator from the CPR Panels of Distinguished Neutrals. If
the Parties cannot agree, they will defer to the CPR to select a mediator. The cost of the mediator shall be borne equally by the Parties. The place of mediation shall be New York, New York, United States of America. Any Dispute not resolved within
[***] (or within such other time period as may be agreed to by the Parties in writing) after appointment of the mediator shall be finally resolved pursuant to Section 12.3. 

12.3 Governing Law and Venue. This Agreement shall be governed by and interpreted in accordance with the internal laws of the State of
Delaware without giving effect to principles of conflicts of laws that would require the application of any other law; provided, however, that matters of intellectual property law shall be determined in accordance with the United States
federal law. Any disputes arising under this Agreement that are not resolved in accordance with Section 12.2 shall be brought solely in Federal or State courts located in New York City, New York. 

  
 30 

 12.4 Entire Agreement. This Agreement (including its Exhibits) sets forth all the
covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersede and terminate all prior agreements and understandings between the Parties with
respect to such subject matter. For clarity, all information relating to the arrangement described in this Agreement that was disclosed pursuant to the Prior CDA or Prior MTA shall be deemed to be Confidential Information under this Agreement and
governed by the terms of ARTICLE 7. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. 

12.5 Assignment. This Agreement may not be assigned, in whole or in part, whether voluntarily or by operation of law, by either Party
without the prior written consent of the other Party, except either Party may assign this Agreement in its entirety to (a) an Affiliate; or (b) a successor entity in connection with a reorganization, merger, consolidation, acquisition, or
other restructuring involving all or substantially all of the voting securities and/or assets of such Party or any of its Affiliates related to this Agreement, provided the successor agrees to assume all of the assigning Party’s rights and
obligations under this Agreement. This Agreement inures to the benefit of and shall be binding upon each Party and their respective successors, heirs and permitted assigns. 

12.6 Severability. If one or more of the provisions in this Agreement are deemed unenforceable by law, then such provision shall be
deemed stricken from this Agreement and the remaining provisions shall continue in full force and effect. 
 12.7 Force Majeure. Both
Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by a Force Majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the
other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition, but no longer than [***]. For purposes of this Agreement,
“Force Majeure” means conditions beyond a Party’s reasonable control or ability to plan for, including acts of God, war, terrorism, civil commotion, labor strike or lock-out; epidemic;
failure or default of public utilities or common carriers; and destruction of production facilities or materials by fire, earthquake, storm or like catastrophe; provided, however, the payment of invoices due and owing under this Agreement
shall not be excused by reason of a Force Majeure affecting the payor. 
 12.8 Notices. Any notice required or permitted to be given
under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if (a) mailed by first class certified or registered mail, postage prepaid,
(b) delivered by express delivery service, or (c) personally delivered, and which notice by personal delivery shall be followed reasonably promptly by an additional notice pursuant to one of clause (a) or (b) above. Unless otherwise
specified in writing, the mailing addresses of the Parties shall be as described below. 

  
 31 

 If to Chimera: 

Project Chimera 
 400 Technology
Square, 10th Floor 
 Cambridge, MA 02139 

U.S.A 
 Attention: Stuart
Chaffee, Ph.D. 
 With a copy to: 

Goodwin Procter LLP „ 
 100
Northern Avenue 
 Boston, MA 02210 

U.S.A. 
 Attention: Christopher
Denn 
 If to GSK: 

GlaxoSmithKline Intellectual Property Development Limited 

980 Great West Road 
 Brentford

 MIDDLESEX 
 TW8 9GS 

United Kingdom 
 Attention:
Senior Vice President, Worldwide Business Development 
 With a copy to: 

GlaxoSmithKline 709 
 Swedeland
Road 
 PO Box 1539 King of Prussia, PA 

U.S.A. 
 Attention: Senior Vice
President, Legal Corporate Functions 
 12.9 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on, nor to be used to interpret, the meaning of the language contained in the particular article or section. 

12.10 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the subsequent enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time
executed by an authorized officer of the waiving Party. 
 12.11 Performance by Affiliates. A Party may perform some or all of its
obligations under this Agreement through Affiliate(s) or may exercise some or all of its rights under this Agreement through Affiliates. Each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall be
responsible for any failure of its Affiliates to comply with the provisions of this Agreement in connection with such performance. In particular and without limitation, all Affiliates of a Party, and all Representatives of such Affiliates, that
receive Confidential Information of the other Party in connection with the performance of the activities pursuant to this Agreement shall be governed and bound by all obligations substantially similar to those set forth in ARTICLE 7. 

  
 32 

 12.12 Counterparts. This Agreement may be executed in one or more identical
counterparts, each of which shall be deemed to be an original, and which collectively shall be deemed to be one and the same instrument. In addition, signatures may be exchanged by facsimile or PDF. 

12.13 Drafting Party. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by
and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties and
their counsels. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in
this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 

12.14 Singular and Plural; Gender. The definitions of the terms herein shall apply equally to the singular and plural forms of the terms
defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The word “will” shall be construed to have the same meaning and effect as the word “shall.” The word
“any” means “any and all” unless otherwise clearly indicated by context. The word “including” will be construed as “including without limitation.” The word “or” is disjunctive but not necessarily
exclusive. 
 12.15 References. Unless the context requires otherwise, (a) any definition of or reference to any agreement,
instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein or therein), (b) any reference to Applicable Law herein shall be construed as referring to such Applicable Law as from time to time enacted, repealed or amended, (c) any reference herein to any person shall
be construed to include the person’s successors and assigns, and (d) all references herein to Articles, Sections or Exhibits, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Exhibits of this
Agreement. 
 ARTICLE 13 

GOOD DATA MANAGEMENT PRACTICES 

13.1 Each Party acknowledges the importance of ensuring that the Research Collaboration is undertaken in accordance with the following
good data management practices (“Good Data Management Practices”): 
 Data are being generated using sound scientific
techniques and processes; 

  
 33 

 Data are being accurately recorded in accordance with good scientific practices by persons
conducting research hereunder; 
 Data are being analyzed appropriately without bias in accordance with good scientific practices; 

Data and results are being stored securely and can be easily retrieved, and Data trails exist to easily demonstrate and/or reconstruct key
decisions made during the conduct of the research, presentations made about the research and conclusions reached with respect to the research. 

13.2 Each Party agrees that it shall carry out the Research Plan and collect and record any data generated therefrom in a manner
consistent with the specific requirements set forth in Exhibit B. At any time during the term of this Agreement, a Party may require changes to the specific requirements set forth in Exhibit B, where such Party reasonably believes such changes are
required to ensure that the Research Plan is undertaken in compliance with Good Data Management Practices. 
 13.3 Each Party shall be
permitted, in its sole discretion and at no additional charge, to undertake on-site compliance audits of the other Party’s Good Data Management Practices on providing the other Party with [***] written
notice of the auditing Party’s intent to do so. 
 ARTICLE 14 

USE OF ANIMALS 
 14.1
Each Party agrees to comply with all relevant statutes, legislation, regulations and guidelines for the care, welfare and ethical treatment of animals used in research in the country where the Research Plan is being performed. In conducting any
research involving the use of animals, each Party further agrees to comply with the “3R” Principles— reducing the number of animals used, replacing animals with non-animal methods whenever
possible and refining the research techniques used. All work must be conducted in adherence to the core principles for animals on research studies identified below. Local customs, norms, practices or laws may be additive to the core principles, but
each Party agrees to comply, at a minimum, with these core principles: 
 access to species appropriate food and water; 

access to species-specific housing, including species-appropriate temperature and humidity levels; 

access to humane care and a program of veterinary care; ability to demonstrate species-specific behaviour; 

adherence to principles of replacement, reduction and refinement in the design of in vivo studies; 

study design reviewed by institutional ethical review panel; 

  
 34 

 commitment to minimizing pain and distress during in vivo studies, and 

work performed by appropriately trained staff. 

14.2 Each Party shall permit the other Party to conduct reasonable inspections (not audits) if announced in advance with written notice,
in order for the inspecting Party to confirm adherence to the above principles and guidelines. To the extent that any material deficiencies are identified as the result of such inspection, the inspected Party shall endeavour in good faith to take
reasonable and practical corrective measures to remedy any such material deficiencies. 
 ARTICLE 15 

COMPLIANCE WITH LAWS 

15.1 Each Party acknowledges that it has read the “Prevention of Corruption - Third Party Guidelines,” hereby attached as
Exhibit E and agrees to perform its obligations under the Agreement in accordance with the principles set out therein. 
 15.2 Each
Party shall comply fully at all times with all Applicable Laws and regulations, including applicable anti-corruption laws, of the territory in which such Party conducts business with the other Party. 

15.3 Either Party shall be entitled to terminate this Agreement immediately on written notice to the other Party if the other Party
fails to perform its obligations in accordance with this ARTICLE 15. The non-terminating Party shall have no claim against the other Party for compensation for any loss of whatever nature by virtue of the
termination of this Agreement in accordance with this ARTICLE 15. To the extent (and only to the extent) that the laws of the territory provide for any such compensation to be paid to the non-terminating upon
the termination of this Agreement, the non-terminating Party hereby expressly agrees to waive (to the extent possible under the laws of the territory) or to repay to the terminating Party any such compensation
or indemnity. 
 ARTICLE 16 

ETHICAL STANDARDS 

16.1 Unless otherwise required or prohibited by Applicable Law, the Parties warrant, to their Knowledge, that in relation to the
performance of this Agreement: 
 they do not employ, engage or otherwise use any child labour in circumstances such that the
tasks performed by any such child labour could reasonably be foreseen to cause either physical or emotional impairment to the development of such child; 

they do not use forced labour in any form (prison, indentured, bonded or otherwise) and their employees are not required to
lodge papers or deposits on starting work; 

  
 35 

 they provide a safe and healthy workplace, presenting no immediate hazards
to their employees. Any housing provided by the Parties to their employees is safe for habitation. The Parties provide access to clean water, food, and emergency healthcare to their employees in the event of accidents or incidents in the workplace;

 they do not discriminate against any employees on any ground (including race, religion, disability or gender); 

they do not engage in or support the use of corporal punishment, mental, physical, sexual or verbal abuse and do not use cruel
or abusive disciplinary practices in the workplace; 
 they pay each employee at least the minimum wage, or a fair
representation of the prevailing industry wage, (whichever is the higher) and provide each employee with all legally mandated benefits; 

they comply with the laws on working hours and employment rights in the countries in which they operate; 

they are respectful of their employees’ right to join and form independent trade unions and freedom of association. 

16.2 The Parties agree that they are responsible for controlling their own supply chain and that they shall encourage compliance with
ethical standards and human rights by any subsequent supply of goods and services that is used by the Parties when performing their obligations under this Agreement. 

16.3 The Parties shall ensure that they have ethical and human rights policies and an appropriate complaints procedure to deal with any
breaches of such policies. 
 [remainder of page intentionally blank] 

  
 36 

 IN WITNESS WHEREOF, the
Parties have by duly authorized persons executed this Agreement as of the date first written above. 
  

			
	PROJECT CHIMERA, INC.	  	GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
		
	Sign: /s/ Stuart Chaffee                            	  	Sign: /s/ Dorcas Murray                            
	Print Name: Stuart Chaffee, Ph.D.	  	Print Name: Dorcas Murray
	Title: Vice President	  	Title: Authorised Signatory, For and on behalf of Glaxo Group Limited Corporate Director
		
	Date: October 3, 2017	  	Date: October 3, 2017

 EXHIBIT A 

Initial Collaboration Targets 

[***] 
 Additional
Collaboration Targets 

 EXHIBIT B 

Research Plan 
 [***] 

 EXHIBIT C 

MATERIAL TRANSFER RECORD FORM 

Capitalized terms used herein that are not defined herein shall have the meanings set forth in the Collaboration Agreement dated October 3, 2017 made
between GSK and Chimera. 
 In connection with the performance of the Collaboration Agreement and pursuant to the terms of therein: 

(i) GSK will transfer to Chimera the GSK Materials set forth below; and/or 

(ii) Chimera will transfer to GSK the Chimera Materials set forth below. 

This Material Transfer Record Form shall be used as the record of all such GSK Material and Chimera Material transfers. 

Transfer Date: 
 Description of Chimera Materials and GSK
Materials, as applicable: 
 Signature - GSK Scientific
Liaison                                        
Date 
 Signature - Chimera Scientific
Liaison                                    Date 

Note: This MTR form is to be completed and signed by the Chimera Scientific Liaison and GSK Scientific Liaison for each transfer. A copy of each completed MTR
is to be timely provided to each Party’s Alliance Manager. This MTR form should not be used to transfer any materials in which Third Parties may have rights, or which may infringe, or violate any intellectual property rights held by any Third
Party. If there are any questions about the appropriateness of a transfer, please contact the institutional representatives identified herein before making the transfer. 

 EXHIBIT D 

Grant Agreement 

 EXHIBIT E 

Prevention of Corruption - Third Party Guidelines 

The GSK Anti-Bribery and Corruption Policy (POL-GSK-007) requires compliance
with the highest ethical standards and all anti-corruption laws applicable in the countries in which GSK (whether through a third party or otherwise) conducts business.
POL-GSK-007 requires all GSK employees and any third party acting for or on behalf of GSK to ensure that all dealings with third parties, both in the private and
government sectors, are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all GSK business. GSK values integrity and transparency and has zero tolerance for corrupt activities of any
kind, whether committed by GSK employees, officers, or third-parties acting for or on behalf of GSK. 
 Corrupt Payments - GSK employees and any
third party acting for or on behalf of GSK, shall not, directly or indirectly, promise, authorize, ratify or offer to make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual (or
at the request of any individual) including a “government official” (as defined in the glossary section) for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage
or to improperly assist the company in obtaining or retaining business. 
 Government Officials - Although GSK’s policy prohibits payments by
GSK or third parties acting for or on its behalf to any individual, private or public, as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate, this policy is particularly
applicable to “payments” of “anything of value” (as defined in the glossary section), or at the request of, “government officials” (as defined in the glossary section). 

Facilitating Payments - For the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as
payments to an individual to secure or expedite the performance of a routine government action by government officials) are no exception to the general rule and therefore prohibited. 

GLOSSARY 
 The terms defined herein should
be construed broadly to give effect to the letter and spirit of the ABAC Policy. GSK is committed to the highest ethical standards of business dealings and any acts that create the appearance of promising, offering, giving or authorising payments
prohibited by this policy will not be tolerated. 
 Anything of Value: this term includes cash or cash equivalents, gifts, services, employment
offers, loans, travel expenses, entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value. 

Payments: this term refers to and includes any direct or indirect offers to pay, promises to pay, authorizations of or payments of anything of value.

 Government Official shall mean: 

 

	•	 	 Any officer or employee of a government or any department, agency or instrument of a government;

  

	•	 	 Any person acting in an official capacity for or on behalf of a government or any department, agency, or
instrument of a government; 

  

	•	 	 Any officer or employee of a company or business owned in whole or part by a government; 

 

	•	 	 Any officer or employee of a public international organization such as the World Bank or United Nations;

  

	•	 	 Any officer or employee of a political party or any person acting in an official capacity on behalf of a
political party; and/or Any candidate for political office

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]